[go: up one dir, main page]

AU2002211280A1 - Piperazin-2-one amides as inhibitors of factor Xa - Google Patents

Piperazin-2-one amides as inhibitors of factor Xa

Info

Publication number
AU2002211280A1
AU2002211280A1 AU2002211280A AU1128002A AU2002211280A1 AU 2002211280 A1 AU2002211280 A1 AU 2002211280A1 AU 2002211280 A AU2002211280 A AU 2002211280A AU 1128002 A AU1128002 A AU 1128002A AU 2002211280 A1 AU2002211280 A1 AU 2002211280A1
Authority
AU
Australia
Prior art keywords
alkyl
methyl
group
compound
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002211280A
Inventor
Erick A. Goldman
Zhaozhong Jon Jia
Wenhao Li
Robert M. Scarborough Jr.
Ting Su
Penglie Zhang
Bing-Yan Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
COR Therapeutics Inc
Original Assignee
COR Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by COR Therapeutics Inc filed Critical COR Therapeutics Inc
Publication of AU2002211280A1 publication Critical patent/AU2002211280A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

PIPERAZIN-2-ONE AMIDES AS INHIBITORS OF FACTOR XA
Field of the Invention
The invention relates to novel piperazin-2-one-containing compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives, and pharmaceutically acceptable compositions thereof which are potent and highly selective inhibitors of isolated factor Xa or when assembled in the prothrombinase complex. These compounds show selectivity for factor Xa versus other proteases of the coagulation (e.g. thrombin, NIIa, flXa) or the fibrinolytic cascades (e.g. plasminogen activators, plasmin). In another aspect, the present invention relates to novel piperazin-2-one-containing compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives factor Xa- inhibiting compounds, and pharmaceutically acceptable compositions thereof which are useful as potent and specific inhibitors of blood coagulation in mammals. In yet another aspect, the invention relates to methods for using these inhibitors as therapeutic agents for disease states in mammals characterized by undesired thrombosis or coagulation disorders.
Background of the Invention Hemostasis, the control of bleeding, occurs by surgical means, or by the physiological properties of vasoconstriction and coagulation. The invention is particularly concerned with blood coagulation and ways in which it assists in maintaining the integrity of mammalian circulation after injury, inflammation, disease, congenital defect, dysfunction or other disruption. Although platelets and blood coagulation are both involved in thrombus formation, certain components of the coagulation cascade are primarily responsible for the amplification or acceleration of the processes involved in platelet aggregation and fibrin deposition.
Thrombin is a key enzyme in the coagulation cascade as well as in hemostasis. Thrombin plays a central role in thrombosis through its ability to catalyze the conversion of fibrinogen into fibrin and through its potent platelet activation activity. Direct or indirect inhibition of thrombin activity has been the focus of a variety of recent anticoagulant strategies as reviewed by Claeson, G., "Synthetic Peptides and Peptidomimetics as Substrates and Inhibitors of Thrombin and Other Proteases in the Blood Coagulation System", Blood Coag. Fibrinol. 5, 411-436 (1994). Several classes of anticoagulants currently used in the clinic directly or indirectly affect thrombin (i.e. heparins, low-molecular weight heparins, heparin-like compounds and coumarins). A prothrombinase complex, including Factor Xa (a serine protease, the activated form of its Factor X precursor and a member of the calcium ion binding, gamma carboxyglutamyl (Gla)-containing, vitamin K dependent, blood coagulation glycoprotein family), converts the zymogen prothrombin into the active procoagulant thrombin. Unlike thrombin, which acts on a variety of protein substrates as well as at a specific receptor, factor Xa appears to have a single physiologic substrate, namely prothrombin. Since one molecule of factor Xa may be able to generate up to 138 molecules of thrombin (Elodi et al., Thromb. Res. 15, 617-619 (1979)), direct inhibition of factor Xa as a way of indirectly inhibiting the formation of thrombin may be an efficient anticoagulant strategy. Therefore, it has been suggested that compounds which selectively inhibit factor Xa may be useful as in vitro diagnostic agents, or for therapeutic administration in certain thrombotic disorders, see e.g., WO 94/13693.
Polypeptides derived from hematophagous organisms have been reported which are highly potent and specific inhibitors of factor Xa. United States Patent 4,588,587 describes anticoagulant activity in the saliva of the Mexican leech, Haementeria officinalis. A principal component of this saliva was shown to be the polypeptide factor Xa inhibitor, antistasin (ATS), by Nutt, E. et al, "The Amino Acid Sequence of Antistasin, a Potent Inhibitor of Factor Xa Reveals a Repeated Internal Structure", J. Biol. Chem., 263, 10162-10167 (1988). Another potent and highly specific inhibitor of Factor Xa, called tick anticoagulant peptide (TAP), has been isolated from the whole body extract of the soft tick Ornithidoros moubata, as reported by Waxman, L., et al, "Tick Anticoagulant Peptide (TAP) is a Novel Inhibitor of Blood Coagulation Factor Xa" Science, 248, 593-596 (1990).
Factor Xa inhibitory compounds which are not large polypeptide-type inhibitors have also been reported including: Tidwell, R.R. et al, "Strategies for Anticoagulation With Synthetic Protease Inhibitors. Xa Inhibitors Versus Thrombin Inhibitors", Thromb. Res., 19, 339-349 (1980); Turner, A.D. et al, "p-Amidino Esters as Irreversible Inhibitors of Factor IXa and Xa and Thrombin", Biochemistry, 25, 4929- 4935 (1986); Hitomi, Y. et al, "Inhibitory Effect of New Synthetic Protease Inhibitor (FUT-175) on the Coagulation System", Haemostasis, 15, 164-168 (1985); Sturzebecher, J. et al, "Synthetic Inhibitors of Bovine Factor Xa and Thrombin. Comparison of Their Anticoagulant Efficiency", Thromb. Res., 54, 245-252 (1989); Kam, CM. et al, "Mechanism Based Isocoumarin Inhibitors for Trypsin and Blood Coagulation Serine Proteases: New Anticoagulants", Biochemistry, 27, 2547-2557 (1988); Hauptmann, J. et al, "Comparison of the Anticoagulant and Antithrombotic Effects of Synthetic Thrombin and Factor Xa Inhibitors", Thromb. Haemost., 63, 220- 223 (1990); and the like.
Others have reported Factor Xa inhibitors which are small molecule organic compounds, such as nitrogen containing heterocyclic compounds which have amidino substituent groups, wherein two functional groups of the compounds can bind to Factor Xa at two of its active sites. For example, WO 98/28269 describes pyrazole compounds having a terminal C(=NH)-NH2 group; WO 97/21437 describes benzimidazole compounds substituted by a basic radical which are connected to a naphthyl group via a straight or branched chain alkylene,-C(=O) or -S(=O)2 bridging group; WO 99/10316 describes compounds having a 4-phenyl-N-alkylamidino- piperidine and 4-phenoxy-N-alkylamidino-piperidine group com ected to a 3- amidinophenyl group via a carboxamidealkyleneamino bridge; and EP 798295 describes compounds having a 4-phenoxy-N-alkylamidino-piperidine group connected to an amidinonaphthyl group via a substituted or unsubstituted sulfonamide or carboxamide bridging group. There exists a need for effective therapeutic agents for the regulation of hemostasis, and for the prevention and treatment of thrombus formation and other pathological processes in the vasculature induced by thrombin such as restenosis and inflammation. In particular, there continues to be a need for compounds which selectively inhibit factor Xa or its precursors. Compounds are needed which selectively or preferentially bind to Factor Xa. Compounds with a higher affinity for binding to Factor Xa than to thrombin are desired, especially those compounds having good bioavailability or other pharmacologically desirable properties.
Summary of the Invention The present invention relates to novel piperazin-2-one-containing compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvate and prodrug derivatives, which have particular biological properties and are useful as potent and specific inhibitors of blood coagulation in mammals. According to the invention, the compounds can act as potent and highly selective inhibitors of isolated Factor Xa or when assembled in the prothrombinase complex. The invention also provides compositions containing such compounds. The compounds of the invention may be used as diagnostic reagents or as therapeutic reagents for disease states in mammals which have coagulation disorders. Thus, the invention further provides methods for preventing or treating a condition in a mammal characterized by undesired thrombosis by administration of a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. Optionally, the methods of the invention comprise administering a pharmaceutical composition of the invention in combination with an additional therapeutic agent such as an antithrombotic and/or a thrombolytic agent and/or an anticoagulant. According to the invention, such conditions include, for example, any thrombotically mediated acute coronary or cerebrovascular syndrome, any thrombotic syndrome occurring in the venous system, any coagulopathy, and any thrombotic complications associated with extracorporeal circulation or instrumentation, and for the inhibition of coagulation in biological samples (e.g. stored blood products and samples). The invention provides a compound of the general formulae I or II:
wherein:
A is a member selected from the group consisting of:
Rl d
Rla, Rlb, Rld, and Rle are each independently a H, C1-6 alkyl, C2-6 alkenyl, C2.6 alkynyl, C3.8cycloalkyl, aryl, -d-βalkylaryl, heterocyclyl, -C1-6alkylheterocyclyl, -(CH2)1-6OH, - (CH2) wθd.6 alkyl, -(CH2)1-6NH2, -(CH2)1-6NHC1-6 alkyl, -(CH2)1-6N(C1-6 alkyl)2, - (CH2)1-6CHNH(COOH), -(CH2)1-6NHC(=O)Cι-6 alkyl, -(CH2)wCHO, -(CH2)ι. 6C(=O)OH, -(CH2)1-6C(-O)OC1-6alkyl, or -(CH2)1-6C O)NH2; wherein Rla, Rlb, Rld, or Rleis optionally substituted with at least one of halo, alkyl, alkylideneamine, arylidenamine, cyano, hydroxy, alkoxy, amino, amidino, guanidino, imino, amido, acid, ester, keto, aldehyde, dioxolane, furanyl, piperidinyl, piperazinyl, pyrrolidinyl, aryl, morpholinyl, and thiomorpholinyldioxide; or Rl and Rl or Rla and Rlc or Rla and Rld or Rld and Rle taken together with the nitrogen atom to which they are each attached can form a substituted or unsubstituted 3 to 8 membered heterocyclic or heteroaromatic amine group which, optionally, contains at least one other heteroatom of N, O or S; wherein Rla, Rlb, Rld, or Rle is optionally substituted with at least one of halo, alkyl, alkylideneamine, arylidenamine, cyano, hydroxy, alkoxy, amino, amidino, guanidino, imino, amido, acid, ester, keto, aldehyde, dioxolane, furanyl, piperidinyl, piperazinyl, pyrrolidinyl, aryl, morpholinyl, and thiomorpholinyldioxide;
Rlc is H, Ci-6alkyl or C3-8cycloalkyl;
R2a, R2b and R2c are each independently a H, Cι-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3- 8cycloalkyl, aryl, -C1-6alkylaryl, heterocyclyl, -C1-6alkylheterocyclyl, -(CH2)1-6OH, - (CH2)1-6OC1-6 alkyl, -(CH2)1-6NH2, -(CH2)1_6NHCι.6 alkyl, alkyl)2, - (CH2)1-6CHNH(COOH), -(CH2)1-6NHC(=O)C1-6 alkyl, -(CH2)!-6CHO, -(CH2)!- 6C(=O)OH, -(CH2)1-6C(=O)OC1.6alkyl, or -(CH2)!-6C(=O)NH2; wherein R2a, R2b and R2c is optionally substituted with at least one of halo, alkyl, alkylideneamine, arylidenamine, cyano, hydroxy, alkoxy, amino, amidino, guanidino, imino, amido, acid, ester, keto, aldehyde, dioxolane, furanyl, piperidinyl, piperazinyl, pyrrolidinyl, aryl, morpholinyl, and thiomorpholinyldioxide; or R2a and R2b or Rla, as set forth above, and R2a or Rl , as set forth above, and R2b taken together with the nitrogen atom to which they are each attached can form a substituted or unsubstituted 3 to 8 membered heterocyclic or heteroaromatic amine group which, optionally, contains at least one other heteroatom of N, O or S; wherein R2a, R2b or R2c is optionally substituted with at least one of halo, alkyl, alkylideneamine, arylidenamine, cyano, hydroxy, alkoxy, amino, amidino, guanidino, imino, amido, acid, ester, keto, aldehyde, dioxolane, furanyl, piperidinyl, piperazinyl, pyrrolidinyl, aryl, morpholinyl, and thiomorpholinyldioxide;
R is, in each occurrence, independently, H, - ^alkyl, -C3-8cycloalkyl, -Co-6alkyl-Od- 6alkyl, -C0-6alkyl-O(CH2)1-4-COOH, -Co-6alkyl-O(CH2)1-4-C(=O)OC1-C6alkyl, -C0-6alkylCOOH, -C0-6alkylCO2C1-6alkyl, -C0-6alkylOCι-6alkyl, -d-ealkylOH, -C0-6alkylCONH2, -C0-6alkylCONHC0-6alkyl, -C0-6alkylCON(C0-6alky)2,
-C0-6alkylCON(CH2)2-6, -C0-6alkylCON(CH2CH2)2O, -C0-6alkylCON(CH2CH2)2SO2 -C0-6alkylCONHaryl, -Co-6alkylNH2, -C0-6alkylNH(d-6alkyl) or -C0-6alkylN(Cι-6alkyl)2.
Q is a member selected from the group consisting of:
Y is S;
R1 is H, -CI, -Br, -I, -F, -OCF3, alkyl, hydroxy, alkoxy, amino, thiol, thioalkyl, thioaryl, or piperizinyl;
J1 is a member selected from the group consisting of:
X is O or S;
R2 is H, -CI, -Br, -I, -F or -Od-6alkyl;
R3 is H, -CI, -Br, -I, -F, -Od-6alkyl, -NHd-6acyl, -NO2, -NHSO2d-4alkyl, -CN,
-NH2, -CONH2, -SO2C1-6alkyl, -SO2NH2, -CO2Cι-6alkyl or -O(CH2)1-4COOH;
R4 and R5 are each independently H, -CI, -Br, -I, -F or -Od-6alkyl;
J2 is a member selected from the group consisting of:
Z is -MR6-, -O- or -S-; R is H, C1-6alkyl or C -8cycloalkyl;
R and R are independently H, -CI, -Br, -I or -F, where at least one of R and R is not hydrogen; and
R9 and R10 are independently H, -CI, -Br, -I or -F, where at least one of R9 and R10 is not hydrogen; and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
Detailed Description of the Invention Definitions
In accordance with the present invention and as used herein, the following terms are defined with the following meanings, unless explicitly stated otherwise.
The term "alkenyl" refers to a trivalent straight chain or branched chain unsaturated aliphatic radical. The term "alkynyl" (or "alkinyl") refers to a straight or branched chain aliphatic radical that includes at least two carbons joined by a triple bond. If no number of carbons is specified alkenyl and alkynyl each refer to radicals having from 2-12 carbon atoms.
The term "alkyl" refers to saturated aliphatic groups including straight-chain, branched-chain and cyclic groups having the number of carbon atoms specified, or if no number is specified, having up to 12 carbon atoms. The term "cycloalkyl" as used herein refers to a mono-, bi-, or tricyclic aliphatic ring having 3 to 14 carbon atoms and preferably 3 to 7 carbon atoms.
As used herein, the terms "carbocyclic ring structure " and " C3-ι6 carbocyclic mono, bicyclic or tricyclic ring structure" or the like are each intended to mean stable ring structures having only carbon atoms as ring atoms wherein the ring structure is a substituted or unsubstituted member selected from the group consisting of: a stable monocyclic ring which is aromatic ring ("aryl") having six ring atoms; a stable monocyclic non-aromatic ring having from 3 to 7 ring atoms in the ring; a stable bicyclic ring structure having a total of from 7 to 12 ring atoms in the two rings wherein the bicyclic ring structure is selected from the group consisting of ring structures in which both of the rings are aromatic, ring structures in which one of the rings is aromatic and ring structures in which both of the rings are non-aromatic; and a stable tricyclic ring structure having a total of from 10 to 16 atoms in the three rings wherein the tricyclic ring structure is selected from the group consisting of: ring structures in which three of the rings are aromatic, ring structures in which two of the rings are aromatic and ring structures in which three of the rings are non-aromatic. In each case, the non-aromatic rings when present in the monocyclic, bicyclic or tricyclic ring structure may independently be saturated, partially saturated or fully saturated. Examples of such carbocyclic ring structures include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), 2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin). Moreover, the ring structures described herein may be attached to one or more indicated pendant groups via any carbon atom which results in a stable structure. The term "substituted" as used in conjunction with carbocyclic ring structures means that hydrogen atoms attached to the ring carbon atoms of ring structures described herein may be substituted by one or more of the substituents indicated for that structure if such substitution(s) would result in a stable compound. The term "aryl" which is included with the term "carbocyclic ring structure" refers to an unsubstituted or substituted aromatic ring, substituted with one, two or three substituents selected from loweralkoxy, loweralkyl, loweralkylamino, hydroxy, halogen, cyano, hydroxyl, mercapto, nitro, thioalkoxy, carboxaldehyde, carboxyl, carboalkoxy and carboxamide, including but not limited to carbocyclic aryl, heterocyclic aryl, and biaryl groups and the like, all of which may be optionally substituted. Examples of suitable aryl groups include, but are not limited to, phenyl, pyridyl, thiophenyl, halophenyl, loweralkylphenyl, naphthyl, biphenyl, phenanthrenyl and naphthacenyl. The term "arylalkyl" which is included with the term "carbocyclic aryl" refers to one, two, or three aryl groups having the number of carbon atoms designated, appended to an alkyl group having the number of carbon atoms designated. Suitable arylalkyl groups include, but are not limited to, benzyl, picolyl, naphthylmethyl, phenethyl, benzyhydryl, trityl, and the like, all of which may be optionally substituted.
As used herein, the term "heterocyclic ring" or "heterocyclic ring system" is intended to mean a substituted or unsubstituted member selected from the group consisting of stable monocyclic ring having from 5-7 members in the ring itself and having from 1 to 4 hetero ring atoms selected from the group consisting of N, O and S; a stable bicyclic ring structure having a total of from 7 to 12 atoms in the two rings wherein at least one of the two rings has from 1 to 4 hetero atoms selected fromN, O and S, including bicyclic ring structures wherein any of the described stable monocyclic heterocyclic rings is fused to a hexane or benzene ring; and a stable tricyclic heterocyclic ring structure having a total of from 10 to 16 atoms in the three rings wherein at least one of the three rings has from 1 to 4 hetero atoms selected from the group consisting of N, O and S. Any nitrogen and sulfur atoms present in a heterocyclic ring of such a heterocyclic ring structure may be oxidized. Unless indicated otherwise the terms "heterocyclic ring" or "heterocyclic ring system" include aromatic rings, as well as non-aromatic rings which can be saturated, partially saturated or fully saturated non-aromatic rings. Also, unless indicated otherwise the term "heterocyclic ring system" includes ring structures wherein all of the rings contain at least one hetero atom as well as structures having less than all of the rings in the ring structure containing at least one hetero atom, for example bicyclic ring structures wherein one ring is a benzene ring and one of the rings has one or more hetero atoms are included within the term "heterocyclic ring systems" as well as bicyclic ring structures wherein each of the two rings has at least one hetero atom. Moreover, the ring structures described herein may be attached to one or more indicated pendant groups via any hetero atom or carbon atom which results in a stable structure. Further, the term "substituted" means that one or more of the hydrogen atoms on the ring carbon atom(s) or nitrogen atom(s) of the each of the rings in the ring structures described herein may be replaced by one or more of the indicated substituents if such replacement(s) would result in a stable compound. Nitrogen atoms in a ring structure may be quaternized, but such compounds are specifically indicated or are included within the term "a pharmaceutically acceptable salt" for a particular compound. When the total number of O and S atoms in a single heterocyclic ring is greater than 1, it is preferred that such atoms not be adjacent to one another. Preferably, there are no more that 1 O or S ring atoms in the same ring of a given heterocyclic ring structure. Examples of monocyclic and bicyclic heterocyclic ring systems, in alphabetical order, are acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H- 1,5,2- dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, lH-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyroazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pryidooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-l,2,5-thiadazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1 ,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl. Preferred heterocyclic ring structures include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, imidazolyl, indolyl, benzimidazolyl, lH-indazolyl, oxazolinyl, or isatinoyl. Also included are fused ring and spiro compounds containing, for example, the above heterocyclic ring structures. As used herein the term "aromatic heterocyclic ring system" has essentially the same definition as for the monocyclic and bicyclic ring systems except that at least one ring of the ring system is an aromatic heterocyclic ring or the bicyclic ring has an aromatic or non-aromatic heterocyclic ring fused to an aromatic carbocyclic ring structure.
The terms "halo" or "halogen" as used herein refer to CI, Br, F or I substituents. The term "haloalkyl", and the like, refer to an aliphatic carbon radicals having at least one hydrogen atom replaced by a CI, Br, F or I atom, including mixtures of different halo atoms. Trihaloalkyl includes trifluoromethyl and the like as preferred radicals, for example.
The term "methylene" refers to -CH-2-. The term "pharmaceutically acceptable salts" includes salts of compounds derived from the combination of a compound and an organic or inorganic acid. These compounds are useful in both free base and salt form. In practice, the use of the salt form amounts to use of the base form; both acid and base addition salts are within the scope of the present invention. "Pharmaceutically acceptable acid addition salt" refers to salts retaining the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
"Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts. Salts derived from pharmaceutically acceptable organic nontoxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperizine, piperidine, N-ethylpiperidine, polyamine resins and the like. Particularly preferred organic nontoxic bases are isopropylamine, diethylamine, ethanolamine, trimethamine, dicyclohexylamine, choline, and caffeine.
"Biological property" for the purposes herein means an in vivo effector or antigenic function or activity that is directly or indirectly performed by a compound of the invention that are often shown by in vitro assays. Effector functions include receptor or ligand binding, any enzyme activity or enzyme modulatory activity, any carrier binding activity, any hormonal activity, any activity in promoting or inhibiting adhesion of cells to an extracellular matrix or cell surface molecules, or any structural role. Antigenic functions include possession of an epitope or antigenic site that is capable of reacting with antibodies raised against it.
In the compounds of the invention, carbon atoms bonded to four non-identical substituents are asymmetric. Accordingly, the compounds may exist as diastereoisomers, enantiomers or mixtures thereof. The syntheses described herein may employ racemates, enantiomers or diastereomers as starting materials or intermediates. Diastereomeric products resulting from such syntheses may be separated by chromatographic or crystallization methods, or by other methods known in the art. Likewise, enantiomeric product mixtures may be separated using the same techniques or by other methods known in the art. Each of the asymmetric carbon atoms, when present in the compounds of the invention, may be in one of two configurations (R or S) and both are within the scope of the present invention.
Compounds
The invention provides a compound of the general formulae I or II:
wherein: A is a member selected from the group consisting of:
Rla, Rlb, Rld, and Rle are each independently a H, C1-6 alkyl, C2-6 alkenyl, -6 alkynyl, C3-8cycloalkyl, aryl, -C1-6alkylaryl, heterocyclyl, -Ci-δalkylheterocyclyl, -(CH2)i-6OH, - (CH2)ι-6OC1-6 alkyl, -(CH2)1-6NH2, -(CH2)1-6NHC1-6 alkyl, -(CH2)1-6N(C1-6 alkyl)2, - (CH2)ι-6CHNH(COOH), -(CH2)ι-6NHC(=O)d-6 alkyl, -(CH2)ι-6CHO, -(CH2)ι- 6C(=O)OH, -(CH2)1-6C(=O)OCι-6alkyl, or -(CH2)ι-6C(=O)NH2; wherein Rla, Rlb, Rld, or Rleis optionally substituted with at least one of halo, alkyl, alkylideneamine, arylidenamine, cyano, hydroxy, alkoxy, amino, amidino, guanidino, imino, amido, acid, ester, keto, aldehyde, dioxolane, furanyl, piperidinyl, piperazinyl, pyrrolidinyl, aryl, morpholinyl, and thiomorpholinyldioxide; or Rla and Rlb or Rla and Rlc or Rla and Rl or Rld and Rle taken together with the nitrogen atom to which they are each attached can form a substituted or unsubstituted 3 to 8 membered heterocyclic or heteroaromatic amine group which, optionally, contains at least one other heteroatom of N, O or S; wherein Rla, Rlb, Rld, or Rle is optionally substituted with at least one of halo, alkyl, alkylideneamine, arylidenamine, cyano, hydroxy, alkoxy, amino, amidino, guanidino, imino, amido, acid, ester, keto, aldehyde, dioxolane, furanyl, piperidinyl, piperazinyl, pyrrolidinyl, aryl, morpholinyl, and thiomorpholinyldioxide;
Rlc is H, Ci-βalkyl or C3-8cycloalkyl; R2a, R2b and R2c are each independently a H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3- scycloalkyl, aryl, -C1-6alkylaryl, heterocyclyl, -C1-6alkylheterocyclyl, -(CH2)1-6OH, - (CH2)1-6Od-6 alkyl, -(CH2)!-6NH2, -(CH2)1-6NHC1-6 alkyl, -(CH2)1-6N(C1-6 alkyl)2, - (CH2)ι-6CHNH(COOH), -(CH2)i-6NHC O)d-6 alkyl, -(CH2)ι-6CHO, -(CH2)ι. 6C(=O)OH, -(CH2)ι-6C(=O)OC1-6alkyl, or -(CH2)1-6C(=O)NH2; wherein R2a, R2b and R2c is optionally substituted with at least one of halo, alkyl, alkylideneamine, arylidenamine, cyano, hydroxy, alkoxy, amino, amidino, guanidino, imino, amido, acid, ester, keto, aldehyde, dioxolane, furanyl, piperidinyl, piperazinyl, pyrrolidinyl, aryl, morpholinyl, and thiomorpholinyldioxide; or R2 and R2b or Rla, as set forth above, and R2a or Rla, as set forth above, and R2b taken together with the nitrogen atom to which they are each attached can form a substituted or unsubstituted 3 to 8 membered heterocyclic or heteroaromatic amine group which, optionally, contains at least one other heteroatom of N, O or S; wherein R2a, R2 or R2° is optionally substituted with at least one of halo, alkyl, alkylideneamine, arylidenamine, cyano, hydroxy, alkoxy, amino, amidino, guanidino, imino, amido, acid, ester, keto, aldehyde, dioxolane, furanyl, piperidinyl, piperazinyl, pyrrolidinyl, aryl, morpholinyl, and thiomorpholinyldioxide;
R is, in each occurrence, independently, H, -Cι-6alkyl, -C3.8cycloalkyl, -C0-6alkyl-Od- 6alkyl, -C0-6alkyl-O(CH2)ι-4-COOH, -Co-6alkyl-O(CH2)1-4-CH))OCι-C6alkyl, -Co-6alkylCOOH, -C0-6alkylCO2d-6alkyl, -C0-6alkylOd-6alkyl, -d-6alkylOH, -Co-ealkylCONHs^Co-ealkylCONHCo-ealkyl.-Co-ealkylCON^o-ea^s, -C0-6alkylCON(CH2)2-6, -C0-6alkylNH2, -Co-6alkylNH(Cι-6alkyl) or -C0-6alkylN(d-6alkyl)2.
Q is a member selected from the group consisting of:
Y is S;
R1 is H, -CI, -Br, -I, -F, -OCF3, alkyl, hydroxy, alkoxy, amino, thiol, thioalkyl, thioaryl, or piperizinyl;
J1 is a member selected from the group consisting of:
X is O or S;
R2 is H, -CI, -Br, -I, -F or -Od-6alkyl;
R3 is H, -CI, -Br, -I, -F, -Od-6alkyl, -NHd-6acyl, -NO2, -NHSO2d-4alkyl, -CN,
-NH2, -CONH2, -SO2C1-6alkyl, -SO2NH2, -CO2C1-6alkyl or -O(CH2)1-4COOH;
R4 and R5 are each independently H, -CI, -Br, -I, -F or -OCι-6alkyl;
J is a member selected from the group consisting of:
Z is -NR -, -O- or -S-; R6 is H, d-6alkyl or C3-8cycloalkyl;
R7 and R8 are independently H, -CI, -Br, -I or -F, where at least one of R7 and R8 is not hydrogen; and
R9 and R10 are independently H, -CI, -Br, -I or -F, where at least one of R9 and R10 is not hydrogen; and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
The invention further provides a compound of the formulae (I) or (II):
wherein:
A is a member selected from the group consisting of:
R is, in each occurrence, independently, H, -C1-6alkyl, -C3-8cycloalkyl, -Cι-6alkylOH, -C0-6alkyl-Od-6alkyl, -C0-6alkyl-O(CH2)ι-4-COOH, -C0-6alkyl-O(CH2)1-4-C(=O)OC1- C6alkyl, -C0-6alkylCOOH, -Co-6alkylCO2d-6alkyl, -C0-6alkylCONH2, -Co-6alkylCONHC0-6alkyl, -Co-6alkylCON(C0-6alky)2, -C0-6alkylCON(CH2)2-6, - C0-6alkylNH2, -C0-6alkylNH(Cι-6alkyl) or -Co-6alkylN(Cι-6alkyl)2. Q is a member selected from the group consisting of:
Y is S;
R1 is H, -CI, -Br, -I or-F, -OMe, NH2, NHMe, NHMe2, -NHCOMe, -NHSO2Me;
J1 is a member selected from the group consisting of:
X is O or S;
R2 is H, -CI, -Br, -I, -F or -Od-6alkyl;
R3 is H, -CI, -Br, -I, -F, -Od-6alkyl, -NHC1-6acyl, -NO2, -NHSO2C1-4alkyl, -CN or -O(CH2)1-4-COOH;
R4 and R5 are each independently H, -CI, -Br, -I, -F or -OCι-6alkyl;
J2 is a member selected from the group consisting of:
Z is -NR -, -O- or -S-;
R6 is H, C1-6alkyl or C3.8cycloalkyl;
R7 and R8 are each independently H, -CI, -Br, -I or -F, where at least one of R7 and R8 is not hydrogen; and
R9 and R10 are each independently H, -CI, -Br, -I or -F, where at least one of R9 and R10 is not hydrogen; and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
The invention further provides a compound of formula (I) or (II):
wherein: A is a member selected from the group consisting of:
R is, in each occurrence, independently, H, -C1-6alkyl, -C3.8cycloalkyl, -d-βalkylOH, -Co-ealkyl-OCrealky^ -Co-ealkyl-O^H^ ^COOH, -C0-6alkyl-O(CH2)ι-4-C(=O)OC1- C6alkyl, -C0-6alkylCOOH, -C0-6alkylCO2d-6alkyl, -C0-6alkylCONH2,
-C0-6alkylCONHC0-6alkyl, -Co-6alkylCON(C0-6alky)2, -C0-6alkylCON(CH2)2-6, - C0-6alkylNH2, -C0-6alkylNH(C1-6alkyl) or -Co-6alkylN(Cι-6alkyl)2.
Q is a member selected from the group consisting of:
Y is S;
R1 is H, -CI, -Br, -I or-F, -OMe, NH2, NHMe, NHMe2; J1 is a member selected from the group consisting of:
X is O or S;
R3 is H, -CI, -Br, -I or -F; R5 is H, -CI, -Br, -I or-F;
J2 is a member selected from the group consisting of:
Z is -NR -, -O- or -S-;
R6 is a H, C1-6 alkyl or C3-8 cycloalkyl;
R7 and R8 are each independently -CI, -Br, -I or -F; and
R9 and R10 are each independently -CI, -Br, -I or -F;
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
The invention provides compounds of formula (I) having the following structure:
wherein: A is a member selected from the group consisting of:
NH NH NH NH
H3C X H3C. X H3C.NΛ. H3C.NA,
_CH3 CHr H2C
NH NH NH NH
H3CNX H3C.NXH3C.NX HSC X
O SMe , N <H>2 , N <H>Me ' . u '
H3C CH3
H3
Ϊ ?"π i N"M r 1 Λχ II ^
ΛαΛc^.c yθ
Me^^ Me N. Me..
MeN^N O^N S^N ζj ^
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof. The invention further provides compounds of formula (I) having the following structure:
wherein: A is a member selected from the group consisting of:
H3C.N . H3C.NX H3C.NΛ. H3C.NX
H3
H3CN
H02C )
N-N02 N-
1 ^ and I ^ i u I I
Me π Me Me
and all pharaiaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
The invention further provides compounds of formula (I) having the following structure:
wherein:
Q is a member selected from the group consisting of:
<r Br ϋr r ύ
H
Or PC
\ , / \ / \,_/ and \ ..'
N5^ \= N= X=N
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
The invention further provides compounds of formula (I) having the following structure:
wherein: A is a member selected from the group consisting of: NH NH NH NH
H3CNA. H3C.NA. H3C.NX H3C X
CH3
H3C
CH,
NH NH u p 1 u r 1
CH HC^
H3
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
The invention further provides compounds of formula (I) having the following structure:
wherein:
R is independently selected from the group consisting of:
H, -CO2H, -CO2Me, -CONH2, -CONHMe, -CONHMe2, -CON(CH2)4, -
CON(CH2)5, -CH2OH, -CH2OMe, -CH2CO2H, -CH2CO2Me, -CH2CONH2, -CH2CH2OH, -CH2CH2OMe, -CH2NH2, -CH2N(Me)2, and -CH3,
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
The invention further provides compounds of formula (I) having the following structure:
wherein:
R is independently selected from the group consisting of: H, -CO2H, -CO2Me, -CONH2, -CONHMe, -CONHMe2, -CON(CH2)4, - CON(CH2)5, -CH2OH, -CH2OMe, -CH2CO2H, -CH2CO2Me, -CH2CONH2, -CH2CH2OH, -CH2CH2OMe, -CH2NH2, -CH2N(Me)2, and -CH3,
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
The invention further provides compounds of formula (I) having the following structure:
wherein: A is a member selected from the group consisting of:
NH NH NH NH
H3C.NA. H3C.NA.H3C.NA. H3C.NA.
O rMe , N SH2 , NHMe . ' ^N »
H3C <.> CH3
i NH I II
H G-/ . M M-e>NMX--X ' O Oκ
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
The invention further provides compounds of formula (I) having the following structure:
wherein
J τ2 is a member selected from the group consisting of:
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
The invention further provides compounds of formula (II) having the following structure:
wherein:
J1 is a member selected from the group consisting of:
,cι
-O- -O- -O' -<A» JA- Jό jfi
H2NOC Q2N 02N Me02S c, -/ rc,i A →r A - A ^AN= >-Mθ
H2N02S Vθ e _J~ -π -OMe A »2 A Λ =/ , \=/ » \==/ ' \=N
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof. The invention also encompasses all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives of the compounds of the invention as set forth herein. The compounds of the invention can exist in various isomeric and tautomeric forms, and all such forms are meant to be included in the invention, along with pharmaceutically acceptable salts, hydrates, solvates and prodrug derivatives of such isomers and tautomers.
The compounds of the invention may be isolated as the free acid or base or converted to salts of various inorganic and organic acids and bases. Such salts are within the scope of the invention. Non-toxic and physiologically compatible salts are particularly useful although other less desirable salts may have use in the processes of isolation and purification.
A number of methods are useful for the preparation of the salts of the compounds as described above and are known to those skilled in the art. For example, the free acid or free base form of a compound of one of the formulae above can be reacted with one or more molar equivalents of the desired acid or base in a solvent or solvent mixture in which the salt is insoluble, or in a solvent like water after which the solvent is removed by evaporation, distillation or freeze drying. Alternatively, the free acid or base form of the product may be passed over an ion exchange resin to form the desired salt or one salt form of the product may be converted to another using the same general process.
The mvention also encompasses prodrug derivatives of the compounds contained herein. The term "prodrug" refers to a pharmacologically inactive derivative of a parent drug molecule that requires biotransformation, either spontaneous or enzymatic, within the organism to release the active drug. Prodrugs are variations or derivatives of the compounds of the invention which have groups cleavable under metabolic conditions. Prodrugs become the compounds of the invention which are pharmaceutically active in vivo, when they undergo solvolysis under physiological conditions or undergo enzymatic degradation. Prodrug compounds of the invention may be called single, double, triple etc., depending on the number of biotransformation steps required to release the active drug within the organism, and indicating the number of functionalities present in a precursor-type form. Prodrug forms often offer advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985 and Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-401, Academic Press, San Diego, CA, 1992). Prodrugs commonly known in the art include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acids with a suitable alcohol, or amides prepared by reaction of the parent acid compound with an amine, or basic groups reacted to form an acylated base derivative. Moreover, the prodrug derivatives of the invention may be combined with other features herein taught to enhance bioavailability.
The compounds of the present invention may also be used alone or in combination or in combination with other therapeutic or diagnostic agents. In certain preferred embodiments, the compounds of the invention may be coadministered along with other compounds typically prescribed for these conditions according to generally accepted medical practice such as anticoagulant agents, thrombolytic agents, or other antithrombotics, including platelet aggregation inhibitors, tissue plasminogen activators, urokinase, prourokinase, streptokinase, heparin, aspirin, or warfarin. The compounds of the present invention may act in a synergistic fashion to prevent reocclusion following a successful thrombolytic therapy and/or reduce the time to reperfusion. These compounds may also allow for reduced doses of the thrombolytic agents to be used and therefore minimize potential hemorrhagic side-effects. The compounds of the invention can be utilized in vivo, ordinarily in mammals such as primates (e.g. humans), sheep, horses, cattle, pigs, dogs, cats, rats and mice, or in vitro. The biological properties of the compounds of the present invention can be readily characterized by methods that are well known in the art, for example by the in vitro protease activity assays and in vivo studies to evaluate antithrombotic efficacy, and effects on hemostasis and hematological parameters, such as are illustrated in the examples.
Diagnostic applications of the compounds of the invention will typically utilize formulations in the form of solutions or suspensions. In the management of thrombotic disorders the compounds of the invention may be utilized in compositions such as tablets, capsules or elixirs for oral administration, suppositories, sterile solutions or suspensions or injectable administration, and the like, or incorporated into shaped articles. Subjects in need of treatment (typically mammalian) using the compounds of the invention can be administered dosages that will provide optimal efficacy. The dose and method of administration will vary from subject to subject and be dependent upon such factors as the type of mammal being treated, its sex, weight, diet, concurrent medication, overall clinical condition, the particular compounds employed, the specific use for which these compounds are employed, and other factors which those skilled in the medical arts will recognize.
Preparation of Compounds
The compounds of the present invention may be synthesized by standard organic chemical synthetic methods as described and referenced in standard textbooks. These methods are well known in the art. See, e.g., Morrison and Boyd, "Organic Chemistry", Allyn and Bacon, Inc., Boston, 1959, et seq.
Starting materials used in any of these methods are commercially available from chemical vendors such as Aldrich, Sigma, Nova Biochemicals, Bachem Biosciences, and the like, or may be readily synthesized by known procedures.
Reactions are carried out in standard laboratory glassware and reaction vessels under reaction conditions of standard temperature and pressure, except where otherwise indicated.
During the synthesis of these compounds, the functional groups of the substituents are optionally protected by blocking groups to prevent cross reaction during coupling procedures. Examples of suitable blocking groups and their use are described in "The Peptides: Analysis, Synthesis, Biology", Academic Press, Vol. 3 (Gross, et al, Eds., 1981) and Vol. 9 (1987), the disclosures of which are incorporated herein by reference. Non-limiting exemplary synthesis schemes are outlined directly below, and specific steps are described in the Examples. The reaction products are isolated and purified by conventional methods, typically by solvent extraction into a compatible solvent. The products may be further purified by column chromatography or other appropriate methods.
SCHEME 1
l.HC MeOH
SCHEME 2
NC
SCHEME 3
NHRld"Rle",MeOH
SCHEME 4
SCHEME 5
SCHEME 6
SCHEME 7
SCHEME 8
SCHEME 9
ddiiooxxaannee
3 S0C12
HOAc, MeOH SCHEME 10
SCHEME 11
fl l SOCL2, MeOH X , BrCH2C02Me Pd C' E'°H » MC J
The following examples are non-limiting embodiments of the present invention, which were made utilizing a method as generally shown in reaction Schemes 1-11 above or by a similar procedure as would be understood by one of skill in the art.
Examples Example 1 Ethyl 2-[4-({4-[(dimethylamino)iminomethyl]phenyl}methyI)-l-[2-(5-chloro(2- thienyloxy))acetyl]-3-oxopiperazin-2-yl] acetate.
Part 1. To a solution of ethyl 3-oxopiperazine-2-acetate (482.7 mg, 2.59 mmol) in DMF (8 mL) at room temperature was added 5-chloro-2-thienyloxyacetic acid (Ewing, W. R., WO 0032590, 2000) (415 mg, 2.16 mmol), DIEA (0.75 mL, 4.32 mmol), and BOP (1.15 g, 2.59 mmol). The solution was stirred at room temperature for 24 hours. The reaction mixture was diluted in EtOAc and water. The organic layer was washed with sat. NaHCO3 and sat. NaCl, dried over MgSO , filtered and concentrated in vacuo to yield ethyl 2-{l-[2-(5-chloro(2-thienyloxy))acetyl]-3-oxopiperazin-2-yl}acetate (0.56 g, 72% yield). MS found for (M+H)+: 361.1.
Part 2. To a solution ethyl 2-{l-[2-(5-chloro(2-thienyloxy))acetyl]-3-oxopiperazin-2- yl}acetate (560 mg, 1.56 mmol) and -bromo-p-tolunitrile (305 mg,1.56 mmol) in 5 mL of DMF was added Cs CO3 (762 mg, 2.34 mmol). After stirring at rt for 24 h, the mixture was diluted with EtOAc and washed with H O. The organic layer was dried over MgSO4, filtered and evaporated in vacuo. Flash chromatography on silica gel (10% EtOAc in DCM) gave ethyl 2-{l-[2-(5-chloro(2-thienyloxy))acetyl]-4-[(4- cyanophenyl)methyl]-3-oxopiperazin-2-yl}acetate (320 mg, 43%). MS found for C13H9N2O3 (M+H)+: 476.
Part 3. A stream of H2S (g) was bubbled through a solution of ethyl 2-{l-[2-(5- chloro(2-thienyloxy))acetyl]-4-[(4-cyanophenyl)methyl]-3-oxopiperazin-2-yl}acetate (320 mg, 0.67 mmol) in 4.5 mL pyridine and 0.5 mL NEt3 until saturation. The mixture was stirred at rt for 4-5 hr and evaporated. The resulting residue was treated with Mel (0.42 mL, 6.74 mmol) in 5 mL acetone at reflux temperature for 1 hr and concentrated to dryness. The resulting residue was treated with a mixture of dimethylamine (1.68 mL of 2 M solution in THF, 3.37 mmol) in acetic acid (0.29 mL, 5.1 mmol) and 4 mL methanol under reflux for 30min. The solvent was removed at reduced pressure and the crude product was purified by HPLC (C18 reversed phase) eluting with 0.1% TFA in H2O/CH3CN to give Ethyl 2-[4-({4-
[(dimethylamino)iminomethyl]phenyl}methyl)-l-[2-(5-chloro(2-thienyloxy))acetyl]-3- oxopiperazin-2-yl]acetate. MS found: (M+H)+: 521.1. Example 2
Ethyl 2-(l-[2-(5-chloro(2-thienyloxy))acetyl]-4-{[4-(inιinopyrrolidinylmethyl) phenyl]methyl}-3-oxopiperazin-2-yl)acetate.
The titled compound was synthesized using a similar procedure to that described in Example 1 using pyrrolidine instead of dimethy la ine in Part 3. MS found: (M+H)+: 580.1.
Example 3 2-[4-({4-[(Dimethylamino)iminomethyl]phenyl}methyl)-l-[2-(5-chloro(2- thienyloxy))acetyl]-3-oxopiperazin-2-yl] acetic acid.
A solution of ethyl 2-[4-({4-[(dimethylamino)iminomethyl]phenyl}methyl)-l-[2-(5- chloro(2-thienyloxy))acetyl]-3-oxopiperazin-2-yl]acetate (40 mg, 0.077 mmol) in 2 mL of methanol and 2 mL of H2O was treated with LiOH (6.46 mg, 0.154 mmol) at rt for 2 h. Methanol was evaporated, and the H O layer was acidified with IN HCl until pH ~ 1-2. The H2O layer was extracted with EtOAc. The organic layer was dried over MgSO4, filtered and evaporated in vacuo and the crude product was purified by HPLC (CI 8 reversed phase) eluting with 0.1% TFA in H2O/CH3CN to give 2-[4-({4-
[(Dimethylamino)iminomethyl]phenyl}methyl)-l-[2-(5-chloro(2-thienyloxy))acetyl]-3- oxopiperazin-2-yl] acetic acid. MS found: (M+H)+: 493.1.
Example 4 2-(l-[2-(5-Chloro(2-thienyloxy))acetyl]-4-{[4-(iminopyrrolidinylmethyl)phenyl] methyl}-3-oxopiperazin-2-yl)acetic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3 using ethyl 2-(l-[2-(5-chloro(2-thienyloxy))acetyl]-4-{[4- (iminopyrrolidinylmethyl)phenyl]methyl} -3 -oxopiperazin-2-yl)acetate. MS found: (M+H)+: 579.1.
Example 5
Ethyl 2-[4-({4-[(dimethylamino)iminomethyl]phenyl}methyl)-l-[(6-chlorobenzo
[b] thiophen-2-yl)sulfonyl] -3-oxopiperazin-2-yl] acetate.
Part 1. To a solution of ethyl 3-oxopiperazine-2-acetate (1J2 g, 6 mmol) in pyridine (15 mL) at rt, was added 6-chlorobenzo[b]thiophene-2-sulfonyl chloride (Ewing, W. R., WO 9937304) (1.33 g, 5 mmol). The mixture was stirred at rt overnignt and evaporated in vacuo. The residue was dissolved in EtOAc and H2O. The organic layer was washed with water, IN HCl, sat. NaHCO , sat. NaCl, dried over Na2SO4 and evaporated to give ethyl 2-{l-[(6-chlorobenzo[b]thiophen-2-yloxy)sulfinyl]-3- oxopiperazin-2-yl} acetate as a solid (1.43 g, 69%% yield). MS found (M+H)+: 417.1.
Part 2. To a solution of ethyl 2-{l-[(6-chlorobenzo[b]thioρhen-2-yloxy)sulfinyl]-3- oxopiperazin-2-yl} acetate (1.04 g, 2.5 mmol) and -bromo-p-tolunitrile (588mg, 3 mmol) in 15 mL of DMF was added Cs2CO3 (1.22 g, 3.75 mmol). After stirring at rt for 24 h, the mixture was diluted with EtOAc and washed with H2O. The organic layer was dried over MgSO4, filtered and evaporated in vacuo. Flash chromatography on silica gel (40%) EtOAc in hexane) gave ethyl 2-{l-[(6-chlorobenzo[b]thiophen-2- yloxy)sulfϊnyl]-4-[(4-cyanophenyl)methyl]-3-oxopiperazin-2-yl}acetate (320 mg, 43%). MS found (M+H)+: 532.1. Part 3. A stream of H2S (g) was bubbled through a solution of ethyl 2-{l-[(6- chlorobenzo[b]thiophen-2-yloxy)sulfinyl]-4-[(4-cyanophenyl)methyl] -3-oxopiperazin-2-yl} acetate (524 mg, 0.985 mmol) in 9 mL pyridine and 1 mL NEt3 until saturation. The mixture was stirred at rt for 24 hr and evaporated. The resulting
5 residue was treated with Mel (0.613 mL, 9.85 mmol) in 5 mL acetone at reflux temperature for 1 hr and concentrated to dryness. The resulting residue was treated with a mixture of dimethylamine (2.48 mL of 2 M solution in THF, 4.92 mmol) in acetic acid (0.42 mL, 7.38 mmol) and 16 mL methanol under reflux for 30min. The solvent was removed at reduced pressure and the crude product was purified by HPLC
10 (C18 reversed phase) eluting with 0.1% TFA in H2O/CH3CN to give ethyl 2-[4-({4- [(dimethylamino)iminomethyl]phenyl}methyl)-l-[(6-chlorobenzo[b]thiophen-2- yl)sulfonyl]-3-oxopiperazin-2-yl]acetate.MS found: (M+H)+: 577.1.
Example 6 15 Ethyl 2-(l-[(6-chlorobenzo[b]thiophen-2-yl)sulfonyl]-4-{[4-
(iminopyrrolidinylmethyl)phenyl]methyl}-3-oxopiperazin-2-yl)acetate.
The titled compound was synthesized using a similar procedure to that described in Example 5 using pyrrolidine instead of dimethylamine in Part 3. MS found: (M+H)+: 20 604.1.
Example 7
Ethyl 2-(l-[(6-chlorobenzo[b]thiophen-2-yl)sulfonyl]-4-{[4-(l-methyl(2-imidazolin-
2-yl))phenyl]methyl}-3-oxopiperazin-2-yl)acetate.
25
The titled compound was synthesized using a similar procedure to that described in Example 5 using N-methylethylenediamine instead of dimethylamine in Part 3. MS found: (M+H)+: 590.1.
Example 8
2-[4-({4-[(dimethylamino)iminomethyl]phenyl}methyl)-l-[(6-chlorobenzo[b] thiophen-2-yl)sulfonyl]-3-oxopiperazin-2-yl] acetic acid.
A solution of ethyl 2-[4-({4-[(dimethylamino)iminomethyl]phenyl}methyl)-l-[(6- chlorobenzo[b]thiophen-2-yl)sulfonyl]-3-oxopiperazin-2-yl]acetate (40 mg, 0.07 mmol) in 2 mL of methanol and 2 mL of H2O was treated with LiOH (5.8 mg, 0.14 mmol) at rt for 2 h. Methanol was evaporated, and the H2O layer was acidified with IN HCl until pH ~ 1-2. The H2O layer was extracted with EtOAc. The organic layer was dried over MgSO4, filtered and evaporated in vacuo and the crude product was purified by HPLC (C18 reversed phase) eluting with 0.1% TFA in H2O/CH3CN to give 2-[4-({4- [(dimethylamino)iminomethyl]phenyl}methyl)-l-[(6-chlorobenzo[b] thiophen-2-yl)sulfonyl]-3-oxopiperazin-2-yl]acetic acid. Mass found: (M+H)+: 550.
Example 9
2-(l- [(6-Chlorobenzo [b] thiophen-2-yl)sulfonyl] -4-{ [4-(iminopyrrolidinylmethyl) phenyl] methyl}-3-oxopiperazin-2-yl)acetic acid.
The titled compound was synthesized using a similar procedure to that described in Example 8 using Ethyl 2-(l-[(6-chlorobenzo[b]thiophen-2-yl)sulfonyl]-4-{[4- (iminopyrrolidinylmethyl)phenyl]methyl} -3 -oxopiperazin-2-yl)acetate. MS found: (M+H)+: 576.1. Example 10
2-(l-[(6-chlorobenzo[b]thiophen-2-yl)sulfonyl]-4-{[4-(l-methyl(2-imidazolin-2- yl))phenyl] methyl}-3-oxopiperazin-2-yl)acetic acid.
The titled compound was synthesized using a similar procedure to that described in Example 8 using ethyl 2-(l-[(6-chlorobenzo[b]thiophen-2-yl)sulfonyl]-4-{[4-(l- methyl(2-imidazolin-2-yl))phenyl]methyl}-3-oxopiperazin-2-yl)acetate. MS found: (M+H)+: 562.1.
Example 11 l-({4-[(Dimethylamino)iminomethyl]phenyl}methyl)-4-[2-(4- chlorophenoxy)acetyl]piperazin-2-one.
Part 1. A mixture of 4-benzyloxycarbonylpiperazin-2-one (3 g, 12.82 mmol), -bromo- p-tolunitrile (6.71 g, 19.23 mmol), and Cs2CO3 (12.53 g, 38.46 mmol) in DMF (10 mL) was stirred at 50°C for 24 hours. The solid was filtered and the filtrate was concentrated. The residue was diluted with EtOAc, washed with sat. NaCl (2x), dried and evaporated. The crude material was subjected to silica gel chromatography to afford phenylmethyl 4-[(4-cyanophenyl)methyl]-3-oxopiperazinecarboxylate (3.5 g, 78%). MS found: (M+H)+: 350.1.
Part 2. A mixture of phenylmethyl 4-[(4-cyanophenyl)methyl]-3- oxopiperazinecarboxylate (1 g, 2.87 mmol) and 10% Pd/C (160 mg) in MeOH (10 mL) was stirred under balloon H2 (1 atm) for 3 hrs. The Pd/C was filtered off through a celite bed. The filtrate was evaporated to give 4-[(2- oxopiperazinyl)methyl]benzenecarbonitrile (600 mg, 97%). MS found: (M+H)+: 216.L Part 3. A mixture of 4-chlorophenol (3 g, 23.44 mmol), tert-butyl bromoacetate (6.82 g, 35.16 mmol), and Cs2CO3 (23.04 g, 70.72 mmol) in DMF (50 mL) was stirred at 50°C for 24 hours. The solid was filtered and the filtrate was concentrated. The residue was 5 diluted with EtOAc and water, washed with sat. NaCl (2x), dried and evaporated. The crude material was subjected to silica gel chromatography to afford tert-butyl 2-(4- chlorophenoxy)acetate (5.2 g, 92%). MS found: (M+H)+: 243.1.
Part 4. tert-butyl 2-(4-chlorophenoxy)acetate (2 g, 8.26 mmol) was dissolved in 10 dioxane. 6 M HCl (10 mL) was added. The mixture was stirred at rt for 1 hr and diluted with EtOAc (20 mL) and water (10 ML). The organic layer was separated and extracted into 0.5 N NaOH (10 mL). H2O layer was washed with EtOAc and acidified with IN HCl, until pH ~ 1-2. The H O layer was extracted with EtOAc. The organic layer was dried over MgSO4, filtered and evaporated in vacuo. Thionyl chloride (5 mL) was 15 added to the residue and the mixture was refluxed for 2 hrs, evaporated in vacuo to give 2-(4-chlorophenoxy)acetyl chloride (1.34 g, 80% yield). MS found: (M+H)+: 205.1.
Part 5. To a solution of 4-[(2-oxopiperazinyl)methyl]benzenecarbonitrile (600 mg, 2.79 mmol) and 2-(4-chlorophenoxy)acetyl chloride (683 mg, 3.35 mmol) in CH3CN (10
20 mL) at rt, was added N-methylmorpholine (1.13 g, 11.16 mmol). The mixture was stirred at rt for 12 hrs. The solvent was evaporated. The residue was diluted with EtOAc, washed with 1 N HCl, sat. NaHCO3, sat. NaCl, dried with Na2SO4 and evaporated to afford 4-({4-[2-(4-chlorophenoxy)acetyl]-2- oxopiperazinyl}methyl)benzenecarbonitrile (750 mg, 70% yield). MS found: (M+H)+:
25 394.1.
Part 6. A stream of HCl (g) was bubbled through a solution of part 5 (400 mg, 1.04 mmol) in MeOH (10 mL) at 0°C for 10 min. The mixture was stirred at rt for 4 hr and evaporated in vacuo. The resulting residue was dissolved in MeOH (30 mL), treated 30 with dimethylamine (2.61 mL of 2 M solution in THF, 5.22 mmol) at reflux temperature for 1 hr and concentrated to dryness. The crude product was purified by HPLC (C18 reversed phase) eluting with 0.1% TFA in H2O/CH3CN to give -({4- [(Dimethylamino)iminomethyl]phenyl}methyl)-4-[2-(4- chlorophenoxy)acetyl]piperazin-2-one. MS found: (M+H)+: 429.1.
Example 12
4-[2-(4-Chlorophenoxy)acetyl]-l-{[4-(l-methyl(2-imidazolin-2- yl))phenyl]methyl}piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 11 using N-methylethylenediamine instead of dimethylamine in part 6. MS found: (M+H)X 441.1.
Example 13 l-{[4-(Azetidinyliminomethyl)phenyl]methyl}-4-[2-(4- chlorophenoxy)acetyl]piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 11 using azetidine instead of dimethylamine in Part 6. MS found: (M+H)+:441.L
Example 14
4-[2-(4-Chlorophenoxy)acetyl]-l-{[4-(iminopyrrolidinylmethyl) phenyl] methyl}piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 11 using pyrrolidine instead of dimethylamine in Part 6. MS found: (M+H)+: 455.1.
Example 15 4-[2-(4-Chlorophenoxy)acetyl]-l-{[4- (iminopiperidylmethyl)phenyl]methyl}piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 11 using piperidine instead of dimethylamine in Part 6. MS found: (M+H)+: 469.1.
Example 16 l-({4-[(Dimethylamino)iminomethyl]phenyl}methyl)-4-[(6- chlorobenzo [b] thiophen-2-yl)sulfonyl] piperazin-2-one.
Part 1. To a solution of phenylmethyl 4-[(4-cyanophenyl)methyl]-3- oxopiperazinecarboxylate (1.29.g, 6 mmol) in pyridine (15 mL) at rt, was added 6- chlorobenzo[b]thiophene-2-sulfonyl chloride (1.33 g, 5 mmol). The mixture was stirred at rt overnignt and evaporated in vacuo. The residue was dissolved in EtOAc and H O. The organic layer was washed with water, IN HCl, sat. NaHCO3, sat. NaCl, dried over Na SO4 and evaporated to give 4-({4-[(6-chlorobenzo[b]thiophen-2- yloxy)sulfmyl]-2-oxopiperazinyl}methyl)benzenecarbonitrile as a solid (1.54 g, 69% yield). MS found (M+H)+: 446.1.
Part 2. A stream of H S (g) was bubbled through a solution of 4-({4-[(6- chlorobenzo[b]thiophen-2-yloxy)sulfinyl]-2- oxopiperazinyl}methyl)benzenecarbonitrile (438 mg, 0.985 mmol) in 9 mL pyridine and 1 mL NEt3 until saturation. The mixture was stirred at rt for 24 hr and evaporated. The resulting residue was treated with Mel (0.613 mL, 9.85 mmol) in 5 mL acetone at reflux temperature for 1 hr and concentrated to dryness. The resulting residue was treated with a mixture of dimethylamine (2.48 mL of 2 M solution in THF, 4.92 mmol) in acetic acid (0.42 mL, 7.38 mmol) and 16 mL methanol at rt for 30 min. The solvent was removed at reduced pressure and the crude product was purified by HPLC (C18 reversed phase) eluting with 0.1% TFA in H2O/CH3CN to give l-({4- [(Dimethylamino)iminomethyl]phenyl}methyl)-4-[(6-chlorobenzo[b]thiophen-2- yl)sulfonyl]piperazin-2-one. MS found: (M+H)+:491.L
Example 17
4-[(6-Chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-{[4-(l-methyl(2-imidazolin-2- yl))phenyl]methyl}piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 16 using N-methylethylenediamine instead of dimethylamine in Part 2. MS found: (M+H)+: 503.1.
Example 18 l-{[4-(Azetidinyliminomethyl)phenyl]methyl}-4-[(6-chlorobenzo[b]thiophen-2- yl)sulfonyl]piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 16 using azetidine instead of dimethylamine in Part 2. MS found: (M+H)+: 503.1. Example 19 4-[(6-Chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-{[4- (iminopyrrolidinylmethyl)phenyl]methyl}piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 16 using pyrrolidine instead of dimethylamine in Part 2. MS found: (M+H)+: 517.1.
Example 20
Ethyl l-{[4-({4-[(6-chlorobenzo[b]thiophen-2-yl)sulfonyl]-2- oxopiperazinyl}methyl)phenyl]iminomethyl}piperidine-4-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 16 using ethyl isonipecotate instead of dimethylamine in Part 2. MS found: (M+H)+: 603.1.
Example 21 l-{[4-({4-[(6-Chlorobenzo[b]thiophen-2-yl)sulfonyl]-2- oxopiperazinyl}methyl)phenyl]iminomethyl}piperidine-4-carboxylic cid.
A solution of Ethyl l-{[4-({4-[(6-chlorobenzo[b]thiophen-2-yl)sulfonyl]-2- oxopiperazinyl}methyl)phenyl]iminomethyl}piperidine-4-carboxylate. (46 mg, 0.077 mmol) in 2 mL of methanol and 2 mL of H2O was treated with LiOH (6.46 mg, 0.154 mmol) at rt for 2 h. Methanol was evaporated, and the H2O layer was acidified with IN HCl until pH ~ 1-2. The H2O layer was extracted with EtOAc. The organic layer was dried over MgSO4, filtered and evaporated in vacuo and the crude product was purified by HPLC (C18 reversed phase) eluting with 0.1% TFA in H2O/CH3CN to give l-{[4-({4-[(6-Chlorobenzo[b]thiophen-2-yl)sulfonyl]-2- oxopiperazinyl}methyl)phenyl]iminomethyl}piperidine-4-carboxylic acid. MS found: (M+H)+: 575.1.
Example 22 l-{[4-(Azetidinyliminomethyl)phenyl]methyl}-4-[(5-chloroindol-2- yl)sulfonyl]piperazin-2-one.
Part 1: To a 25 mL round bottom flask was added phenylmethyl 3- oxopiperazinecarboxylate (1.17 g, 5 mmol), dry DMF (10 mL), -bromo-p-tolunitrile (1 g, 5 mmol) and Cs2CO3 (4. 89 g, 15 mmol). The mixture was stirred at room temperature for 20 hours. EtOAc and water were added to the reaction. The organic layer was washed with water, dried over MgSO4, and concentrated in vacuo to afford phenylmethyl 4-[(4-cyanophenyl)methyl]-3-oxopiperazinecarboxylate as light yellow organic oil (1.43 g, 82%). MS found: (M+H)+: 350.
Part 2. A mixture of phenylmethyl 4-[(4-cyanophenyl)methyl]-3- oxopiperazinecarboxylate (1 g, 2.87 mmol) and 10% Pd/C (160 mg) in MeOH (10 mL) was stirred under balloon H (1 atm) for 3 hrs. The Pd/C was filtered off through a celite bed. The filtrate was evaporated to give 4-[(2- ' oxopiperazinyl)methyl]benzenecarbonitrile (600 mg, 97%>). MS found: (M+H)+: 216.L
Part 3: A solution of 5-chloroindole (25 J g, 169 mmol) in anhydrous THF (500 mL) was cooled with a dry ice-acetone bath, and n-BuLi (80 mL of 2.45 M solution in hexanes) was added dropwise over 15 minutes. The reaction was stirred in the cold for 10 minutes, then a solution of di-t-butyl dicarbonate (46.2 g, 212 mmol) in THF (150 mL) was added dropwise over 20 minutes. The reaction was stirred at room temperature overnight. EtOAc (500 mL) and 50 mL of water (50 mL) were added. The aqueous layer was extracted with EtOAc (300 mL), and the combined organics were washed with water (200 mL), dried over MgSO4, filtered and the Filtrate were concentrated to give brown oil. This oil was subjected to flash column chromatography on silica gel first with 100% hexane, then with 0.5%) EtOAc/Hexanes then with 1% EtOAc/Hexanes as eluents. The appropriate factions were combined and concentrated to give tert-butyl 5-chloroindolecarboxylate (39.34 g, 92%) as clear, nearly colorless oil that crystallized on the high vacuum pump overnight.
Part 4: A solution of tert-butyl 5-chloroindolecarboxylate (20.0 g, 79.5 mmol) from Part 1 in THF (200 mL) was cooled with a dry ice-acetone bath under Ar, and n-BuLi (44 mL of 2.0 M solution in hexanes, 87.5 mmol) was added over 15 minutes. The reaction mixture was allowed to stir in the cold for 10 minutes, then added dropwise (over 10 minutes) via double-ended needle to a pre-cooled (with a dry ice-acetone bath) solution of SO2 (80 g) in THF (100 mL). The reaction was allowed to stir at room temperature for 2 hrs. then concentrated to give a brown foam. This foam was dissolved in methylene chloride (200 mL) and the solution was cooled to 0C in an ice- water bath. To this was added sulfuryl chloride (7 mL, 87.5 mmol) dropwise over 5 minutes. The ice bath was removed and the reaction was stirred at room temperature overnight. Much solid (LiCl) had begun to form during the addition of SO2Cl . The reaction was filtered and the filtrate was concentrated to give a dark residue. This residue was washed through a plug of silica gel with 1L of 30% DCM/Hexanes. The solvent was evaporated and the residue was subjected to flash column chromatography on silica gel using first 10% DCM/Hexanes, then 15% DCM/Hexanes. The appropriate fractions were combined and concentrated to give tert-butyl 5-chloro-2- (chlorosulfonyl)indolecarboxylate (14.34 g, 52%>) as an off- white solid.
Part 5: Phenylmethyl 4-[(4-cyanophenyl)methyl]-3-oxopiperazinecarboxylate from Part 2 (0.35 g, 1 mmol) was dissolved in methylene chloride (5 mL) and pyridine (5 mL). Five minutes later 0.3502 g of tert-butyl 5-chloro-2-(chlorosulfonyl)indolecarboxylate (0.35 g) from Part 4 was added to the reaction. The mixture was stirred at room temperature for five hours. The solvent was removed in vacuo. Water and methylene chloride was added to the crude brown oil. The organic layers were combined, dried over MgSO4, concentrated in vacuo to tert-butyl 5-chloro-2-({4-[(4- cyanophenyl)methyl]-3-oxopiperazinyl}sulfinyloxy)indolecarboxylate as a light yellow solid (0.40 g, 75%). MS found: (M+H)+: 530.
Part 6: tert-Butyl 5-chloro-2-({4-[(4-cyanophenyl)methyl]-3- oxopiperazinyl}sulfinyloxy)indolecarboxylate from Part 5 (50 mg, 0.09 mmol) was dissolved in dry EtOH (10 mL) and HCl gas was bubbled through the solution until saturation. The mixture was stirred at room temperature for 24 hours. The solvent was removed in vacuo and the residue was redissolved in EtOH, to this was added azetidine HCl salt (50 mg, 0.53 mmol) and triethyl amine (84 mM, 0.6 mmol). The mixture was stirred at room temperature for 5 hours and purified by HPLC (C18 reversed phase) eluting with 0.1% TFA in H2O/CH3CN to afford l-{[4- (Azetidinyliminomethyl)phenyl]methyl}-4-[(5-chloroindol-2-yl)sulfonyl]piperazin-2- one (34 mg, 74%). MS found (M+H)+: 486.
Example 23
Ethyl l-{[4-({4-[(5-chloroindol-2-yl)sulfonyl]-2- oxopiperazinyl}methyl)phenyl]iminomethyl}piperidine-4-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 22 using ethyl isonipecotate instead of azetidine in Part 6. MS found: (M+H)+: 586.
Example 24 l-({4- [(8-Aza-l,4-dioxaspiro [4.5] dec-8-yl)iminomethyl] phenyl} methyl)-4- [(5- chloroindol-2-yl)sulfonyl]piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using 1, 4-dioxa-8-azaspiro[4, 4]decane instead of azetidine in Part 6. MS found: (M+H)+: 572.
Example 25
4-[(5-chloroindol-2-yl)sulfonyl]-l-({4-
[(ethylmethylamino)iminomethyl]phenyl}methyl)piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using N-ethylmethylamine instead of azetidine in Part 6. MS found: (M+H)+: 488.
Example 26 l-[(4-{[4-(Dimethylamino)piperidyl]iminomethyl}phenyl)methyl]-4-[(6- chloroindol-2-yl)sulfonyl] piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using 4-(dimethylamino)-piperidine instead of azetidine in Part 6. MS found: (M+H)+: 557.
Example 27 l-({4-[(Dimethylamino)iminomethyl]phenyl}methyl)-4-[(6-chloroindol-2- yl)sulfonyl]piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using dimethylamine instead of azetidine in part 6. MS found: (M+H)+ 474.
Example 28 '
4-[(6-Chloroindol-2-yl)sulfonyl]-l-{[4-
(iminopiperidylmethyl)phenyl]methyl}piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 piperidine instead of azetidine in part 6. MS found: (M+H)+: 514.
Example 29
4-[(6-Chloroindol-2-yl)sulfonyl]-l-{[4- (iminopyrrolidinylmethyl)phenyl] methyl} iperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 pyrrolidine instead of azetidine in part 6. MS found: (M+H)+: 500.
Example 30 l-{[4-({[2-(Dimethylamino)ethyl]methylamino}iminomethyl)phenyl]methyl}-4-[(6- chloroindol-2-yl)sulfonyl]piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using N, N, N'-trimethylethylenediamine instead of azetidine in Part 6. MS found: (M+H)+: 531.
Example 31
4-[(6-Chlorobenzo[b]thiophen-2-yl)suϊfonyl]-l-{[4-(l-methyl(2-imidazolin-2- yl))phenyl]methyl}piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using N-methylethylenediamine instead of azetidine in part 6. MS found: (M+H)+: 486.
Example 32
4-[(5-ChIoroindol-2-yl)suIfonyI]-l-({4- [imino(methylpropylamino)methyl]phenyl}methyl)piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using N-methyl-N-propylamine instead of azetidine in Part 6. MS found: (M+H)+: 502.
Example 33 l-({4-[(4-Bromopiperidyl)iminomethyl]phenyl}methyl)-4-[(5-chloroindol-2- yl)sulfonyl]piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using 4-bromopiperidine instead of azetidine in Part 6. MS found: (M+H)+: 592.
Example 34 4-[(5-chloroindol-2-yl)sulfonyl]-l-({4-[imino(methylprop-2- enylamino)methyl]phenyl}methyl)piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using N-methylallylamine instead of azetidine in Part 6. MS found: (M+H)+: 500.
Example 35
4-[(5-Chloroindol-2-yl)sulfonyl]-l-[(4-{[(2- furylmethyl)methylamino]iminomethyl}phenyl)methyl]piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using N-methylfurfurylamine instead of azetidine in Part 6. MS found: (M+H)+: 540.
Example 36 l-({4-[(Butylmethylamino)iminomethyl]phenyl}methyl)-4-[(5-chloroindol-2- yl)sulfonyl]piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using N-methylbutylamine instead of azetidine in Part 6. MS found: (M+H)+: 516.
Example 37
4-[(5-Chloroindol-2-yl)sulfonyl]-l-({4-[imino(4- oxopiperidyl)methyl]phenyl}methyl)piperazin-2-one.
1 -( {4- [(8 - Aza- 1 ,4-dioxaspiro [4.5] dec-8 -yl)iminomethy ljphenyl} methyl)-4- [(5 - chloroindol-2-yl)sulfonyl]piperazin-2-one from example 24 (10 mg) was dissolved in a solution of 4N HCl in dioxane (3 mL). The mixture was refluxed for 6 hours and concentrated in vacuo. The residue was purified by HPLC (C18 reversed phase) eluting with 0.1% TFA in H2O/CH3CN to HPLC to afford 4-[(5-Chloroindol-2-yl)sulfonyl]-l- ({4-[imino(4-oxopiperidyl)methyl]phenyl}methyl)piperazin-2-one.(7 mg, 71%). MS found: (M+H)+: 528.
Example 38
4-[(5-Chloroindol-2-yl)sulfonyl]-l-({4-
[(cyclohexylmethylamino)iminomethyl]phenyl}methyl)piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in
Example 22 using N-methylcyclohexylamine instead of azetidine in Part 6. MS found:
(M+H)+: 542.
Example 39 l-{[4-({4-[(5-Chloroindol-2-yl)sulfonyl]-2- oxopiperazmyl}methyl)phenyl]iminomethyl}piperidine-4-carboxylic cid.
The titled compound was synthesized using a similar procedure to that described in Example 3 using Ethyl l-{[4-({4-[(5-chloroindol-2-yl)sulfonyl]-2- oxopiperazinyl}methyl)phenyl]iminomethyl}piperidine-4-carboxylate from example 23. MS found: (M+H)+: 558.
Example 40
4-[(5-Chloroindol-2-yl)suIfonyl]-l-[(4-{imino[methyI(2- phenylethyl)amino]methyl}phenyl)methyl]piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using N-methylphenethylamine instead of azetidine in Part 6. MS found: (M+H)+: 564.
Example 41
4-[(5-Chloroindol-2-yl)sulfonyl]-l-[(4-{imino[methyl(2-(2- pyridyl)ethyl)amino]methyl}phenyl)methyl]piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using 4-[2-(methylamino)ethyl]pyridine instead of azetidine in Part 6. MS found: (M+H)+: 565.
Example 42 l-({4-[(But-3-ynylmethylamino)iminomethyl]phenyl}methyl)-4-[(5-chloroindol-2- yl)sulfonyl]piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using N-methyl- -alaninenitrile instead of azetidine in Part 6. MS found: (M+H)+: 513.
Example 43
4-[(5-Chloroindol-2-yl)sulfonyl]-l-[(4-
{imino[methylbenzylamino]methyl}phenyl)methyl]piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using N-methylbenzylamine instead of azetidine in Part 6. MS found: (M+H)+: 550.
Example 44 l-[(4-{[(2,2-Dimethoxyethyl)methylamino]iminomethyl}phenyl)methyl]-4-[(5- chloroindol-2-yl)sulfonyl]piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using methylaminoacetaldehyde dimethylacetal instead of azetidine in Part 6. MS found: (M+H)+: 548.
Example 45
4-[(5-Chloroindol-2-yl)sulfonyl]-l-({4-[imino(4- pyrrolidinylpiperidyl)methyl]phenyl}methyl)piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using 4-pyrrolidinopiperidhιe instead of azetidine in Part 6. MS found: (M+H)+: 583.
Example 46
4-[(5-ChIoroindol-2-yI)sulfonyl]-l-[(4-{[(l,3-dioxolan-2- ylmethyl)methylamino]iminomethyl}phenyl)methyl]piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using 2-methylaminomethyl-l,3-dioxalone instead of azetidine in Part 6. MS found: (M+H)+: 546.
Example 47 4-[(5-Chloroindol-2-yl)sulfonyl]-l-({4-
[imino(methylamino)methyl]phenyl}methyl)piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using methylamine instead of azetidine in Part 6. MS found: (M+H)+: 460.
Example 48
4-[(5-Chloroindol-2-yl)sulfonyl]-l-[(4-{imino[methyl(2- oxoethyl)amino]methyl}phenyl)methyl]piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 37 using 4-[(5-Chloroindol-2-yl)sulfonyl]-l-[(4-{[(l,3-dioxolan-2- ylmethyl)methylamino]iminomethyl}phenyl)methyl]piperazin-2-one from example 46. MS found: (M+H)+: 502.
Example 49
4-[(5-Chloroindol-2-yl)sulfonyl]-l-({4-
[(ethynylmethylamino)iminomethyl]phenyl}methyl)piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 37 as a minor product. MS found: (M+H)+: 484.
Example 50 4- [(5-Chloroindol-2-yl)sulfonyl] -l-({4- [imino(methylprop-2- ynylamino)methyl]phenyl}methyl)piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using N-methylpropargylamine instead of azetidine in Part 6. MS found: (M+H)+: 498.
Example 51 l-{[4-(Azetidinylazetidinylidenemethyl)phenyl]methyl}-4-[(5-chloroindol-2- yl)sulfonyl]piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 as a minor product. MS found: (M+H)+: 529.
Example 52 4-[(6-Chlorobenzo[b]thiophen-2-yl)suIfonyl]-l-({4-[imino(methylprop-2- ynylamino)methyl]phenyl}methyl)piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using 5 -chloro-2-thienyloxy acetic acid (Ewing, W. R., WO 0032590, 2000) instead of tert-butyl 5-chloro-2-(chlorosulfonyl)indolecarboxylate in Part 5 and N-methylpropargylamine instead of azetidine in Part 6. MS found: (M+H)+: 515.
Example 53
4-[(6-Chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-[(4-{imino[methyl(2- phenylethyl)amino]methyl}phenyl)methyl]piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using 5-chloro-2-thienyloxyacetic acid instead of tert-butyl 5-chloro-2- (chlorosulfonyl)indolecarboxylate in Part 5 and N-methylphenethylamine instead of azetidine in Part 6. MS found: (M+H)+: 581.
Example 54 4-[(6-Chlorobenzo[b]thiophen-2-yl)suIfonyl]-l-[(4-{imino[methyl(2-(2- pyridyl)ethyl)amino]methyl}phenyl)methyl]piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using 5-chloro-2-thienyloxyacetic acid instead of tert-butyl 5-chloro-2- (chlorosulfonyl)indolecarboxylate in Part 5 and 4-[2-(methylamino)ethyl]pyridine instead of azetidine in Part 6. MS found: (M+H)+: 582.
Example 55 4- [(6-Chlorobenzo [b] thiophen-2-yl)sulfonyl] -l-({4- [imino(methylprop-2- enylamino)methyl]phenyl}methyl)piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using 5-chloro-2-thienyloxyacetic acid instead of tert-butyl 5-chloro-2- (chlorosulfonyl)indolecarboxylate in Part 5 and N-methylallylamine instead of azetidine in Part 6. MS found: (M+H)+: 517.
Example 56
4-[(6-chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-[(4-{[(l,3-dioxolan-2- ylmethyl)methylamino]iminomethyl}phenyl)methyl]piperazin-2-one.
The titled compound was synthesized using a similar procedure to that described in Example 22 using 5-chloro-2-thienyloxyacetic acid instead of tert-butyl 5-chloro-2- (chlorosulfonyl)indolecarboxylate in Part 5 and 2-methylaminomethyl-l,3-dioxalone instead of azetidine in Part 6. MS found: (M+H)+: 563.1. Example 57
Methyl (2R)-4-[(6-chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-[(4-{[(l,3-dioxolan-2- ylmethyl)methylamino]iminomethyl}phenyl)methyl]-6-oxopiperazine-2- carboxylate.
Part 1: To a precooled (ice bath) mixture of Z-D-Dap-OH (7.1 g, 29.8 mmol) and anhydrous MeOH (23 mL), was added slowly SOCl2 (2.2 mL, 30 mmol). The mixture was allowed to warm to room temperature and stirred at this temperature for 18 hours. The solvent was removed in vacuo. The product was crystallized to afford 3-amino-N- [(benzyloxy)carbonyl]-D-alanine methyl ester hydrochloride (7.5 g, 87%).
Part 2: To a stirred mixture of 3-amino-N-[(benzyloxy)carbonyl]-D-alanine methyl ester from Part 1 (free base: 6.2 g, 24.5 mmol), DIEA (3.5g, 26Jmmol), and anhydrous THF (65 mL), was added methyl bromoacetate (3.1 g, 24.5 mmol) in anhydrous THF (10 ml). The mixture was stirred at rt for 24 hours. The suspension was filtered and the filtrate evaporated. The residue was treated with Et2O, filtered, and the solvent evaporated. The oily residue (7.8 g) was dissolved in EtOH (100 mL) and hydrogenated over 10% Pd/C. The catalyst was filtered off, the solvent removed and the product crystallized form EtOH/Et2O to afford 2.7 g (70%) of methyl (2R)-6- oxopiperazine-2-carboxylate as colorless crystals.
Part 3: The titled compound was synthesized using a similar procedure to that described in Example 1 using methyl (2R)-6-oxopiperazine-2-carboxylate instead of ethyl 3- oxopiperazine-2-acetate in Part 1 and 2-methylaminomethyl-l,3-dioxalone instead of dimethylamine in Part 3. MS found: (M+H)+: 621. Example 58
(2R)-4-[(6-Chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-[(4-{[(l,3-dioxolan-2- ylmethyl)methylamino]iminomethyl}phenyl)methyl]-6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3 using Methyl (2R)-4-[(6-chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-[(4- {[(l,3-dioxolan-2-ylmethyl)methylamino]iminomethyl}phenyl)methyl]-6- oxopiperazine-2-carboxylate. MS found: (M+H)+: 607.1.
Example 59
Methyl (2R)-l-{[4-(azetidinyliminomethyl)phenyl]methyl}-4-[(6- chlorobenzo [b] thiophen-2-yl)sulfonyl] -6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 1 using methyl (2R)-6-oxopiperazine-2-carboxylate instead of ethyl 3- oxopiperazine-2-acetate in Part 1 and azetidine instead of dimethylamine in Part 3. MS found: (M+H)+: 561.0.
Example 60
(2R)-l-{ [4-(Azetidinyliminomethyl)phenyl] methyl}-4- [(6-chlorobenzo [b] thiophen- 2-yl)sulfonyl]~6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 547.1. Example 61
Methyl (2R)-4- [(6-chlorobenzo [b] thiophen-2-yl)sulfonyl]-l-{ [4-
(iminopyrrolidinylmethyl)phenyl]methyl}-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 1 using methyl (2R)-6-oxopiperazine-2-carboxylate instead of ethyl 3- oxopiperazine-2-acetate in Part 1 and pyrrolidine instead of dimethylamine in Part 3. MS found: (M+H)+: 575.1.
Example 62
(2R)-4-[(6-Chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-{[4-
(iminopyrrolidinylmethyl)phenyl]methyl}-6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 561.1.
Example 63
Methyl (2R)-4-[(6-chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-{[4- (iminopiperidylmethyl)phenyl]methyl}-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 1 using methyl (2R)-6-oxopiperazine-2-carboxylate instead of ethyl 3- oxopiperazine-2-acetate in Part 1 and piperidine instead of dimethylamine in Part 3. MS found: (M+H)+: 589.1. Example 64
(2R)-4-[(6-Chlorobenzo[b]thiophen-2-yI)suIfonyl]-l-{[4-
(iminopiperidylmethyl)phenyl]methyl}-6-oxopiperazine-2-carbox lie acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 575.1.
Example 65 Methyl (2R)-4- [(6-chlorobenzo [b]thiophen-2-yl)sulfonyl]-l-[(4-{ [4-
(ethoxycarbonyl)piperidyl]iminomethyl}phenyl)methyl]-6-oxopiperazine-2- carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 1 using methyl (2R)-6-oxopiperazine-2-carboxylate instead of ethyl 3- oxopiperazine-2-acetate in Part 1 and ethyl isonipecotate instead of dimethylamine in Part 3. MS found: (M+H)+: 661.1.
Example 66 (2R)-l-({4-[(4-Carboxypiperidyl)iminomethyl]phenyl}methyl)-4-[(6- chlorobenzo [b] thiophen-2-yl)sulfonyl] -6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 619.1. Example 67
Methyl (2R)-4-[(6-chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-({4-
[imino(methylprop-2-enylamino)methyl]phenyl}methyl)-6-oxopiperazine-2- carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 1 using methyl (2R)-6-oxopiperazine-2-carboxylate instead of ethyl 3- oxopiperazine-2-acetate in Part 1 and N-methylallylamine instead of dimethylamine in Part 3. MS found: (M+H)+: 575.1.
Example 68
(2R)-4-[(6-Chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-({4-[imino(methylprop-2- enylamino)methyl]phenyl}methyl)-6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in
Example 3. MS found: (M+H) : 561.1.
Example 69
Methyl (2R)-4-[(6-chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-({4- [imino(methylprop-2-ynylamino)methyI]phenyI}methyl)-6-oxopiperazine-2- carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 1 using methyl (2R)-6-oxopiperazine-2-carboxylate instead of ethyl 3- oxopiperazine-2-acetate in Part 1 and N-methylpropargylamine instead of dimethylamine in Part 3. MS found: (M+H)+: 573.1.
Example 70 (2R)-4-[(6-Chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-({4-[imino(methylprop-2- ynylamino)methyl]phenyl}methyl)-6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 559.1.
Example 71
Methyl (2R)-4-[(6-chlorobenzo[b]thiophen-2-yl)suIfonyl]-l-({4-
[imino(methylamino)methyl]phenyl}methyl)-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 1 using methyl (2R)-6-oxopiperazine-2-carboxylate instead of ethyl 3- oxopiperazine-2-acetate in Part 1 and N-methylamine instead of dimethylamine in Part 3. MS found: (M+H)+: 535.L
Example 72
(2R)-4-[(6-Chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-({4- [imino(methylamino)methyl]phenyl}methyl)-6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 521.1. Example 73
Methyl (2R)-4-[(6-chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-[(4-{[(2- cyanoethyl)methyIamino]iminomethyl}phenyI)methyl]-6-oxopiperazine-2- carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 1 using methyl (2R)-6-oxopiperazine-2-carboxylate instead of ethyl 3- oxopiperazine-2-acetate in Part 1 and N-methyl- -alaninenitrile instead of dimethylamine in Part 3. MS found: (M+H)+: 586.1.
Example 74
(2R)-4-[(6-Chlorobenzo[b]thiophen-2-yl)suIfonyl]-l-[(4-{[(2- cyanoethyl)methyIamino]iminomethyl}phenyl)methyl]-6-oxopiperazine-2- carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 574.1.
Example 75
Methyl (2R)-l-({4-[(dimethylamino)iminomethyl]phenyl}methyl)-4-[(6- chlorobenzo[b]thiophen-2-yl)sulfonyl]-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 1 using methyl (2R)-6-oxopiperazine-2-carboxylate instead of ethyl 3- oxopiperazine-2-acetate in Part 1. MS found: (M+H)+: 549.1.
Example 76
(2R)-l-({4- [(Dimethylamino)iminomethyl] phenyl}methyl)-4- [(6- chlorobenzo[b]thiophen-2-yl)sulfonyl]-6-oxopiperazine-2-carboxylic cid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 535.1.
Example 77
Methyl (2R)-4-[(6-chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-[(4-{imino[methyl(2- phenylethyl)amino]methyl}phenyl)methyl]-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 1 using methyl (2R)-6-oxopiperazine-2-carboxylate instead of ethyl 3- oxopiperazine-2-acetate in Part 1 and N-methylphenethylamine instead of dimethylamine in Part 3. MS found: (M+H)+: 639.1.
Example 78
(2R)-4-[(6-Chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-[(4-{imino[methyl(2- phenylethyl)amino]methyl}phenyl)methyl]-6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 625.1.
Example 79 Methyl (2R)-4-[(6-chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-[(4-{imino[methyl(2-(2- pyridyl)ethyl)amino]methyl}phenyl)methyl]-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 1 using methyl (2R)-6-oxopiperazine-2-carboxylate instead of ethyl 3- oxopiperazine-2-acetate in Part 1 and 4-[2-(methylamino)ethyl]pyridine instead of dimethylamine in Part 3. MS found: (M+H)+: 640.1.
Example 80
(2R)-4-[(6-Chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-[(4-{imino[methyl(2-(2- pyridyl)ethyl)amino]methyl}phenyl)methyl]-6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 626.1.
Example 81
Methyl (2R)-4-[(6-chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-{[4-(l-methyl(2- imidazolin-2-yl))phenyl]methyl}-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 1 using methyl (2R)-6-oxopiperazine-2-carboxylate instead of ethyl 3- oxopiperazine-2-acetate in Part 1 and N-methylethylenediamine instead of dimethylamine in Part 3. MS found: (M+H)+: 561.
Example 82 (2R)-4-[(6-Chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-{[4-(l-methyl(2-imidazolin-2- yl))phenyl]methyl}-6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in
Example 3. MS found: (M+H)+: 547.
Example 83
Methyl (2R)-l-[(4-{[(l,3-dioxolan-2- yImethyl)methyIamino]iminomethyl}phenyl)methyl]-4-[(5-methylindol-2- yl)sulfonyl]-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 22. MS found: (M+H)+: 604.
Example 84
(2R)-4-[(5-Chloroindol-2-yl)sulfonyl]-l-[(4-{[(l,3-dioxolan-2- ylmethyl)methylamino]iminomethyl}phenyl)methyl]-6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 590.
Example 85 Methyl (2R)-l-{[4-(azetidinyliminomethyl)phenyl]methyl}-4-[(5-chloroindol-2- yl)sulfonyl]-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 22. MS found: (M+H)+: 544.
Example 86
(2R)-l-{[4-(Azetidinyliminomethyl)phenyl]methyI}-4-[(5-chloroindol-2- yl)sulfonyl] -6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 530.1.
Example 87 Methyl (2R)-4-[(5-chloroindol-2-yl)sulfonyl]-l-{[4-
(iminopyrrolidinylmethyl)phenyl]methyl}-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 22. MS found: (M+H)+: 558. Example 88
(2R)-4-[(5-Chloroindol-2-yl)suIfonyl]-l-{[4-
(iminopyrrolidinylmethyl)phenyl]methyl}-6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 544.
Example 89
Methyl (2R)-4-[(5-chloroindoI-2-yl)sulfonyl]-l-{[4- (iminopiperidyImethyl)phenyl]methyl}-6-oxopiperazine-2-carboxyIate.
The titled compound was synthesized using a similar procedure to that described in Example 22. MS found: (M+H)+: 572.
Example 90
(2R)-4-[(5-Chloroindol-2-yl)sulfonyl]- 1 - { [4-(iminopiperidylmethyl)phenyl]methyl} -6- oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 558.
Example 91
Methyl (2R)-4-[(5-chloroindol-2-yl)sulfonyl]-l-[(4-{[4- (ethoxycarbonyl)piperidyl]immomethyl}phenyl)methyI]-6-oxopiperazine-2- carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 22. MS found: (M+H)+: 644.
Example 92 (2R)-l-({4-[(4-Carboxypiperidyl)iminomethyl]phenyl}methyl)-4-[(5-chloroindol-2- yl)sulfonyl]-6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 602.
Example 93
Methyl (2R)-4-[(5-chloroindol-2-yl)sulfonyl]-l-({4-[imino(methylprop-2- enyIamino)methyl]phenyl}methyl)-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 22. MS found: (M+H)+: 558.
Example 94 (2R)-4-[(5-Chloroindol-2-yl)sulfonyl]-l-({4-[imino(methylprop-2- enylamino)methyl]phenyl}methyl)-6-oxopiperazine-2-carboxylic cid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 544.0.
Example 95 Methyl (2R)-4-[(5-chloroindol-2-yl)sulfonyl]-l-({4-[imino(methylprop-2- ynylamino)methyl]phenyl}methyl)-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 22. MS found: (M+H)+: 556.1.
Example 96
(2R)-4-[(5-Chloroindol-2-yl)sulfonyl]-l-({4-[imino(methylprop-2- ynylamino)methyl]phenyl}methyl)-6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesizqd using a similar procedure to that described in Example 3. MS found: (M+H)+: 542.
Example 97
Methyl (2R)-4-[(5-chloroindol-2-yl)sulfonyl]-l-({4- [imino(methylamino)methyl]phenyl}methyl)-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 22. MS found: (M+H)+: 518.1/
Example 98 (2R)-4-[(5-Chloroindol-2-yl)sulfonyl]-l-({4- [imino(methylamino)methyl]phenyl}methyl)-6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 504.
Example 99
Methyl (2R)-4-[(5-chloroindol-2-yl)sulfonyl]-l-[(4-{[(2- cyanoethyl)methyIamino]iminomethyl}phenyl)methyl]-6-oxopiperazine-2- carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 22. MS found: (M+H)+: 571.
Example 100
(2R)-4-[(5-Chloroindol-2-yl)sulfonyl]-l-[(4-{[(2- cyanoethyl)methylamino]iminomethyl}phenyl)methyl]-6-oxopiperazine-2- carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 557.1.
Example 101
Methyl (2R)-l-({4-[(dimethylamino)iminomethyl]phenyl}methyl)-4-[(5- chloroindol-2-yl)sulfonyl]-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 22. MS found: (M+H)+: 532.1.
Example 102
(2R)-l-({4-[(Dimethylamino)iminomethyl]phenyl}methyl)-4-[(5-chloroindol-2- yl)sulfonyl]-6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 518.1.
Example 103
Methyl (2R)-4-[(5-chloroindol-2-yl)sulfonyl]-l-[(4-{imino[methyl(2- phenylethyl)amino]methyl}phenyl)methyl]-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 22. MS found: (M+H)+: 622.1.
Example 104 (2R)-4-[(5-Chloroindol-2-yl)sulfonyl]-l-[(4-{imino[methyl(2- phenylethyl)amino] methyl}phenyl)methyl] -6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 608.1.
Example 105 Methyl (2R)-4-[(5-chloroindol-2-yl)sulfonyl]-l-[(4-{imino[methyl(2-(2- pyridyl)ethyl)amino]methyl}phenyl)methyl]-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in
Example 22. MS found: (M+H)+: 623.1.
Example 106
(2R)-4-[(5-Chloroindol-2-yl)sulfonyl]-l-[(4-{imino[methyl(2-(2- pyridyl)ethyl)amino]methyl}phenyl)methyl]-6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 609.1.
Example 107
Methyl (2R)-4-[(5-chloroindol-2-yl)sulfonyl]-l-{[4-(l-methyl(2-imidazolin-2- yl))phenyl] methyl}-6-oxopipe azine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 22. MS found: (M+H)+: 544.1. Example 108
(2R)-4-[(5-Chloroindol-2-yl)sulfonyl]-l-{[4-(l-methyl(2-imidazolin-2- yl))phenyl] methyl}-6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 530.
Example 109
Methyl (2R)-4-[(5-chloroindol-2-yl)sulfonyl]-l-[(4-{imino[methyl(2- oxoethyl)amino]methyl}phenyl)methyl]-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 37 using compound of example 83. MS found: (M+H)+: 560.1.
Example 110
(2R)-4-[(5-Chloroindol-2-yl)sulfonyl]-l-[(4-{imino[methyl(2- oxoethyl)amino]methyl}phenyl)methyl]-6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 546.1.
Example 111
Methyl (2R)-4-[(6-chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-[(4-{imino[methyl(2- oxoethyl)amino]methyl}phenyl)methyl]-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 37 using compound of example 57. MS found: (M+H)+: 577.
Example 112 (2R)-4-[(6-Chlorobenzo[b]thiophen-2-yl)sulfonyl]-l-[(4-{imino[methyl(2- oxoethyl)amino]methyl}phenyl)methyl]-6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 563.
Example 113
Methyl (2R)-l-{[4-(azetidinylazetidinylidenemethyl)phenyl]methyI}-4-[(5- chloroindol-2-yl)sulfonyl]-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 22 as a minor product in the synthesis of compound of example 85. MS found: (M+H)+: 585.
Example 14
(2R)-l-{[4-(Azetidinylazetidinylidenemethyl)phenyl]methyl}-4-[(5-chIoroindol-2- yl)sulfonyl] -6-oxopiperazine-2-carboxylic acid. The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 571.
Example 115 Methyl (2R)-l-{[4-(azetidinylazetidinylidenemethyl)phenyl]methyl}-4-[(6- chlorobenzo[b]thiophen-2-yl)sulfonyl]-6-oxopiperazine-2-carboxylate.
The titled compound was synthesized using a similar procedure to that described in Example 1 in the synthesis of compound of example 59 as a minor product. MS found: (M+H)+: 602.
Example 116
(2R)-l-{[4-(Azetidinylazetidinylidenemethyl)phenyl]methyl}-4-[(6- chlorobenzo[b]thiophen-2-yl)sulfonyl]-6-oxopiperazine-2-carboxylic acid.
The titled compound was synthesized using a similar procedure to that described in Example 3. MS found: (M+H)+: 588.
Compositions and Formulations
Compositions or formulations of the compounds of the invention are prepared for storage or administration by mixing the compound having a desired degree of purity with physiologically acceptable carriers, excipients, stabilizers etc., and may be provided in sustained release or timed release formulations. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical field, and are described, for example, in Remington 's Pharmaceutical Sciences, Mack Publishing Co., (A.R. Gennaro edit. 1985). Such materials are nontoxic to the recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, acetate and other organic acid salts, antioxidants such as ascorbic acid, low molecular weight (less than about ten residues) peptides such as polyarginine, proteins, such as serum albumin, gelatin, or immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidinone, amino acids such as glycine, glutamic acid, aspartic acid, or arginine, monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, mannose or dextrins, chelating agents such as EDTA, sugar alcohols such as mannitol or sorbitol, counterions such as sodium and/or nonionic surfactants such as Tween®, Pluronics® or polyethyleneglycol.
Dosage formulations of the compounds of the invention to be used for therapeutic administration must be sterile. Sterility is readily accomplished by filtration through sterile membranes such as 0.2 micron membranes, or by other conventional methods. Formulations typically will be stored in lyophilized form or as an aqueous solution. The pH of the preparations of the invention typically will be between about 3 and about 11, more preferably from about 5 to about 9 and most preferably from about 7 to about 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of cyclic polypeptide salts. While the preferred route of administration is by injection, other methods of administration are also anticipated such as intravenously (bolus and/or infusion), subcutaneously, intramuscularly, colonically, rectally, nasally or intraperitoneally, employing a variety of dosage forms such as suppositories, implanted pellets or small cylinders, aerosols, oral dosage formulations and topical formulations such as ointments, drops and dermal patches. The compounds of the invention are desirably incorporated into shaped articles such as implants which may employ inert materials such as biodegradable polymers or synthetic silicones, for example, Silastic, silicone rubber or other polymers commercially available. The compounds of the invention may also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of lipids, such as cholesterol, stearylamine or phosphatidylcholines. The compounds of the invention may also be delivered by the use of antibodies, antibody fragments, growth factors, hormones, or other targeting moieties, to which the compound molecules are coupled. The compounds of the invention may also be coupled with suitable polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxy-propyl-methacrylamide-phenol, polyhydroxyethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the factor Xa inhibitors of the invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example polylactic acid, polyglycolic acid, copolymers of poly lactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels. Polymers and semipermeable polymer matrices may be formed into shaped articles, such as valves, stents, tubing, prostheses and the like.
Therapeutic compound liquid formulations generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by hypodermic injection needle.
Therapeutically effective dosages may be determined by either in vitro or in vivo methods. For each particular compound of the present invention, individual determinations may be made to determine the optimal dosage required. The range of therapeutically effective dosages will naturally be influenced by the route of administration, the therapeutic objectives, and the condition of the patient. For injection by hypodermic needle, it may be assumed the dosage is delivered into the body's fluids. For other routes of administration, the absorption efficiency must be individually determined for each inhibitor by methods well known in pharmacology. Accordingly, it may be necessary for the therapist to titer the dosage and modify the route of administration as required to obtain the optimal therapeutic effect. The determination of effective dosage levels, that is, the dosage levels necessary to achieve the desired result, will be within the ambit of one skilled in the art. Typically, applications of compound are commenced at lower dosage levels, with dosage levels being increased until the desired effect is achieved.
A typical dosage of the compounds and compositions of the invention range from about 0.001 mg/kg to about 1000 mg/kg, preferably from about 0.01 mg/kg to about 100 mg/kg, and more preferably from about 0.10 mg/kg to about 20 mg/kg. Advantageously, the compounds of the invention may be administered several times daily. Other dosage regimens may also be useful (e.g. single daily dose and/or continuous infusion). Typically, about 0.5 to about 500 mg of a compound or mixture of compounds of the invention, as the free acid or base form or as a pharmaceutically acceptable salt, is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, dye, flavor, etc., as called for by accepted pharmaceutical practice. The amount of active ingredient in these compositions is such that a suitable dosage in the range indicated is obtained.
Typical adjuvants which may be incorporated into tablets, capsules and the like are a binder such as acacia, corn starch or gelatin, and excipient such as microcrystalline cellulose, a disintegrating agent like com starch or alginic acid, a lubricant such as magnesium stearate, a sweetening agent such as sucrose or lactose, or a flavoring agent. When a dosage form is a capsule, in addition to the above materials it may also contain a liquid carrier such as water, saline, a fatty oil. Other materials of various types may be used as coatings or as modifiers of the physical form of the dosage unit. Sterile compositions for injection can be formulated according to conventional pharmaceutical practice. For example, dissolution or suspension of the active compound in a vehicle such as an oil or a synthetic fatty vehicle like ethyl oleate, or into a liposome may be desired. Buffers, preservatives, antioxidants and the like can be incorporated according to accepted pharmaceutical practice.
The preferred compounds of the present invention are characterized by their ability to inhibit thrombus formation with acceptable effects on classical measures of coagulation parameters, platelets and platelet function, and acceptable levels of bleeding complications associated with their use. Conditions characterized by undesired thrombosis would include those involving the arterial and venous vasculature.
With respect to the coronary arterial vasculature, abnormal thrombus formation characterizes the rupture of an established atherosclerotic plaque which is the major cause of acute myocardial infarction and unstable angina, as well as also characterizing the occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty (PTC A).
With respect to the venous vasculature, abnormal thrombus formation characterizes the condition observed in patients undergoing major surgery in the lower extremities or the abdominal area who often suffer from thrombus formation in the venous vasculature resulting in reduced blood flow to the affected extremity and a predisposition to pulmonary embolism. Abnormal thrombus formation further characterizes disseminated intravascular coagulopathy commonly occurs within both vascular systems during septic shock, certain viral infections and cancer, a condition wherein there is rapid consumption of coagulation factors and systemic coagulation which results in the formation of life-threatening thrombi occurring throughout the microvasculature leading to widespread organ failure.
The compounds of the invention are useful for the treatment or prophylaxis of those diseases which involve the production and/or action of factor Xa/prothrombinase complex. The compounds of this present invention, selected and used as disclosed herein, find utility as a diagnostic or therapeutic agent for preventing or treating a condition in a mammal characterized by undesired thrombosis or a disorder of coagulation. Disease states treatable or preventable by the administration of compounds of the invention include, without limitation, occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty, thrombus formation in the venous vasculature, disseminated intravascular coagulopathy, the treatment of reocclusion or restenosis of reperfused coronary arteries, thromboembolic complications of surgery and peripheral arterial occlusion, a condition wherein there is rapid consumption of coagulation factors and systemic coagulation which results in the formation of life-threatening thrombi occurring throughout the microvasculature leading to widespread organ failure, hemorrhagic stroke, renal dialysis, blood oxygenation, and cardiac catheterization.
Accordingly, the invention provides a method for preventing or treating a condition in a mammal characterized by undesired thrombosis which administers to a mammal a therapeutically effective amount of a compound of the invention, as described herein. Conditions for prevention or treatment include, for example, (a) the treatment or prevention of any thrombotically mediated acute coronary syndrome including myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, (b) the treatment or prevention of any thromboticaHy mediated cerebrovascular syndrome including embolic stroke, thrombotic stroke or transient ischemic attacks, (c) the treatment or prevention of any thrombotic syndrome occurring in the venous system including deep venous thrombosis or pulmonary embolus occurring either spontaneously or in the setting of malignancy, surgery or trauma, (d) the treatment or prevention of any coagulopathy including disseminated intravascular coagulation (including the setting of septic shock or other infection, surgery, pregnancy, trauma or malignancy and whether associated with multi-organ failure or not), thrombotic thrombocytopenic purpura, thromboangiitis obliterans, or thrombotic disease associated with heparin induced tlirombocytopenia, (e) the treatment or prevention of thrombotic complications associated with extracorporeal circulation (e.g. renal dialysis, cardiopulmonary bypass or other oxygenation procedure, plasmapheresis), (f) the treatment or prevention of thrombotic complications associated with instrumentation (e.g. cardiac or other intravascular catheterization, intra-aortic balloon pump, coronary stent or cardiac valve), and (g) those involved with the fitting of prosthetic devices. Anticoagulant therapy is also useful to prevent coagulation of stored whole blood and to prevent coagulation in other biological samples for testing or storage. Thus the compounds of the invention can be added to or contacted with any medium containing or suspected to contain factor Xa and in which it is desired that blood coagulation be inhibited, e.g., when contacting the mammal's blood with material such as vascular grafts, stents, orthopedic prostheses, cardiac stents, valves and prostheses, extra corporeal circulation systems and the like. Thus, the compounds of the invention also find utility in a method for inhibiting the coagulation of biological samples by administration of a compound of the invention.
BIOLOGICAL ACTIVITY EXAMPLES
Evaluation of the compounds of the invention is guided by in vitro protease activity assays (see below) and in vivo studies to evaluate antithrombotic efficacy, and effects on hemostasis and hematological parameters.
The compounds of the present invention are dissolved in buffer to give solutions containing concentrations such that assay concentrations range from about 0 to 100 μM. In the assays for thrombin, prothrombinase and factor Xa, a synthetic chromogenic substrate is added to a solution containing test compound and the enzyme of interest and the residual catalytic activity of that enzyme is determined spectrophotometrically. The IC5 of a compound is determined from the substrate turnover. The IC50 is the concentration of test compound giving 50% inhibition of the substrate turnover. The compounds of the present invention desirably have an IC50 of less than about 500 nM in the factor Xa assay, preferably less than about 200 nM, and more preferred compounds have an IC50 of about 100 nM or less in the factor Xa assay. The compounds of the present invention desirably have an IC50 of less than about 4.0 μM in the prothrombinase assay, preferably less than 200 nM, and more preferred compounds have an IC50 of about 10 nM or less in the prothrombinase assay.
The compounds of the present invention desirably have an IC50 of greater than about
1.0 μM in the thrombin assay, preferably greater than about 10.0 μM, and more preferred compounds have an IC50 of greater than about 100.0 μM in the thrombin assay.
Amidolvtic Assays for determining protease inhibition activity
The factor Xa and thrombin assays are performed at room temperature, in 0.02 M Tris-HCl buffer, pH 7.5, containing 0.15 M NaCl. The rates of hydrolysis of the para-nitroanilide substrate S-2765 (Chromogenix) for factor Xa, and the substrate Chromozym TH (Boehringer Mannheim) for thrombin following preincubation of the enzyme with inhibitor for 5 minutes at room temperature, and were determined using the Softmax 96-well plate reader (Molecular Devices), monitored at 405 nm to measure the time dependent appearance of p-nitroaniline. The prothrombinase inhibition assay is performed in a plasma free system with modifications to the method described by Sinha, U. et al, Thromb. Res., 75, 427-436 (1994). Specifically, the activity of the prothrombinase complex is determined by measuring the time course of thrombin generation using the p-nitroanilide substrate Chromozym TH. The assay consists of preincubation ( 5 minutes) of selected compounds to be tested as inhibitors with the complex formed from factor Xa (0.5 nM), factor Na (2 nM), phosphatidyl serine:phosphatidyl choline (25:75, 20 μM) in 20 mM Tris-HCl buffer, pH 7.5, containing 0.15 M ΝaCl, 5 mM CaCl2 and 0.1% bovine serum albumin. Aliquots from the complex-inhibitor mixture are added to prothrombin (1 nM) and Chromozym TH (0.1 mM). The rate of substrate cleavage is monitored at 405 nm for two minutes. Eight different concentrations of inhibitor are assayed in duplicate. A standard curve of thrombin generation by an equivalent amount of untreated complex are used for determination of percent inhibition.
Antithrombotic Efficacy in a Rabbit Model of Venous Thrombosis A rabbit deep vein thrombosis model as described by Hollenbach, S. et al.,
Thromb. Haemost. 71, 357-362 (1994), is used to determine the in-vivo antithrombotic activity of the test compounds. Rabbits are anesthetized with I.M. injections of Ketamine, Xylazine, and Acepromazine cocktail. A standardized protocol consists of insertion of a thrombogenic cotton thread and copper wire apparatus into the abdominal vena cava of the anesthetized rabbit. A non-occlusive thrombus is allowed to develop in the central venous circulation and inhibition of thrombus growth is used as a measure of the antithrombotic activity of the studied compounds. Test agents or control saline are administered through a marginal ear vein catheter. A femoral vein catheter is used for blood sampling prior to and during steady state infusion of test compound. Initiation of thrombus formation begins immediately after advancement of the cotton thread apparatus into the cenfral venous circulation. Test compounds are administered from time = 30 min to time = 150 min at which the experiment is terminated. The rabbits are euthanized and the thrombus excised by surgical dissection and characterized by weight and histology. Blood samples are analyzed for changes in hematological and coagulation parameters.
Effects of Compounds in Rabbit Venous Thrombosis model
Administration of compounds in the rabbit venous thrombosis model demonstrates antithrombotic efficacy at the higher doses evaluated. There are no significant effects of the compound on the aPTT and PT prolongation with the highest dose (100 μg/kg + 2.57 μg/kg/min). Compounds have no significant effects on hematological parameters as compared to saline controls. All measurements are an average of all samples after steady state administration of vehicle or (D)-Arg-Gly-Arg- thiazole. Values are expressed as mean + SD.
Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. It should be understood that the foregoing discussion and examples merely present a detailed description of certain preferred embodiments. It will be apparent to those of ordinary skill in the art that various modifications and equivalents can be made without departing from the spirit and scope of the invention. All the patents, journal articles and other documents discussed or cited above are herein incorporated by reference.

Claims

WHAT IS CLAIMED IS:
1. A compound of the formulae (I) or (II):
wherein: A is a member selected from the group consisting of:
Rl , Rlb, Rld, and Rlβ are each independently a H, Cι-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8cycloalkyl, aryl, -Ci-6alkylaryl, heterocyclyl, -C1-6alkylheterocyclyl, -(CH2)i-6OH, - (CH2)i-6OCi-6 alkyl, -(CH2)ι-6NH2, -(CH2)1-6NHC1-6 alkyl, -(CH2)1.6N(C1-6 alkyl)2, - (CH2)1-6CHNH(COOH), -(CH2)ι-6NHC(=O)Cι_6 alkyl, -(CH2)ι-6CHO, -(CH2)ι- 6C(=O)OH, -(CH2)ι-6C(-O)OCι-6alkyl, or -(CH2)ι-6C(=O)NH2; wherein Rla, Rlb, Rld, or Rleis optionally substituted with at least one of halo, alkyl, alkylideneamine, arylidenamine, cyano, hydroxy, alkoxy, amino, amidino, guanidino, imino, amido, acid, ester, keto, aldehyde, dioxolane, furanyl, piperidinyl, piperazinyl, pyrrolidinyl, aryl, morpholinyl, and thiomorpholinyldioxide; or Rla and Rlb or Rla and Rlc or Rla and Rld or Rld and Rle taken together with the nitrogen atom to which they are each attached can form a substituted or unsubstituted 3 to 8 membered heterocyclic or heteroaromatic amine group which, optionally, contains at least one other heteroatom of N, O or S; wherein Rla, Rlb, Rld, or Rleis optionally substituted with at least one of halo, alkyl, alkylideneamine, arylidenamine, cyano, hydroxy, alkoxy, amino, amidino, guanidino, imino, amido, acid, ester, keto, aldehyde, dioxolane, furanyl, piperidinyl, piperazinyl, pyrrolidinyl, aryl, morpholinyl, and thiomorpholinyldioxide;
Rlc is H, C1-6alkyl or C .8cycloalkyl;
R2a, R2b and R2c are each independently a H, Cι-6 alkyl, C2-6 alkenyl, C -6 alkynyl, C3- 8cycloalkyl, aryl, -C1-6alkylaryl, heterocyclyl, -Ci-ealkylheterocyclyl, -(CH2)1-6OH, - (CH2)1-6OCι-6 alkyl, -(CH2)!-6NH2, -(CH^NHQ-s alkyl, -(CH2),,N(C,, alkyl)2, - (CH2)1-6CHNH(COOH), -(CH2)1-6NHC(=O)C1-6 alkyl, -(CH2)!-6CHO, -(CH2)ι- 6C(=O)OH, -(CH2)1-6C(=O)OC1-6alkyl, or -(CH2)1-6C(-O)NH2; wherein R2a, R2b and R2c is optionally substituted with at least one of halo, alkyl, alkylideneamine, arylidenamine, cyano, hydroxy, alkoxy, amino, amidino, guanidino, imino, amido, acid, ester, keto, aldehyde, dioxolane, furanyl, piperidinyl, piperazinyl, pyrrolidinyl, aryl, morpholinyl, and thiomorpholinyldioxide; or R2 and R2b or Rl , as set forth above, and R2a or Rla, as set forth above, and R2b taken together with the nitrogen atom to which they are each attached can form a substituted or unsubstituted 3 to 8 membered heterocyclic or heteroaromatic amine group which, optionally, contains at least one other heteroatom of N, O or S; wherein R2a, R2b or R c is optionally substituted with at least one of halo, alkyl, alkylideneamine, arylidenamine, cyano, hydroxy, alkoxy, amino, amidino, guanidino, imino, amido, acid, ester, keto, aldehyde, dioxolane, furanyl, piperidinyl, piperazinyl, pyrrolidinyl, aryl, morpholinyl, and thiomorpholinyldioxide;
R is, in each occurrence, independently, H, -C1-6alkyl, -C -8cycloalkyl, -Co-galkyl-OCi- 6alkyl, -C0-6alkyl-O(CH2)1-4-COOH, -Co-6alkyl-O(CH2)ι-4-C(=O)OC1-C6alkyl, -Co-6alkylCOOH, -Co-6alkylCO2C1-6alkyl, -Co-ealkylOQ-ealkyl, - -galkylOH, -C0-6alkylCONH2, -C0-6alkylCONHC0-6alkyl, -C0-6alkylCON(C0-6alky)2, -Co-6alkylCON(CH2)2-6, -C0-6alkylCON(CH2CH2)2O, -C0-6alkylCON(CH2CH2)2SO2 -C0-6alkylCONHaryl) -C0-6alkylNH2, -C0-6alkylNH(Cι-6alkyl) or -C0-6alkylN(Cι-6alkyl)2.
Q is a member selected from the group consisting of:
Y is S;
R1 is H, -CI, -Br, -I, -F, -OCF , alkyl, hydroxy, alkoxy, amino, thiol, thioalkyl, thioaryl, or piperizinyl;
J is a member selected from the group consisting of:
X is O or S;
R2 is H, -CI, -Br, -I, -F or -OC1-6alkyl;
R3 is H, -CI, -Br, -I, -F, -OCι-6alkyl, -MHCι-6acyl, -NO2, -NHSO2Cι-4alkyl, -CN,
-NH2, -CONH2, -SO2Cι^alkyl, -SO2NH2, -CO2Cι-6alkyl or -O(CH2)!-4COOH;
R4 and R5 are each independently H, -CI, -Br, -I, -F or -OCr6alkyl;
j2 is a member selected from the group consisting of:
Z is -MR6-, -O- or -S-;
R6 is H, C1-6alkyl or C3-8cycloalkyl;
R7 and R8 are independently H, -CI, -Br, -I or -F, where at least one of R7 and R8 is not hydrogen; and
R9 and R10 are independently H, -CI, -Br, -I or -F, where at least one of R9 and R10 is not hydrogen; and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof.
2. A compound of claim 1, wherein:
A is a member selected from the group consisting of:
R is, in each occurrence, independently, H, -C1-6alkyl, -C3-8cycloalkyl, -Co-ealkyl-OC 6alkyl, -Co-6alkyl-O(CH2)i-4-COOH, -C0-6alkyl-O(CH2)1-4-C O)OC1-C6alkyl, -C0-6alkylCOOH, -C0-6alkylCO2C1-6alkyl, -Co-ealkylOd-galkyl, -Cι-6alkylOH, -C0-6alkylCONH2, -Co-6alkylCONHC0-6alkyl, -C0-6alkylCON(C0-6alky)2, -Co-6alkylCON(CH2)2-6, -C0-6alkylCON(CH2CH2)2O, -C0-6alkylCON(CH2CH2)2SO2 -C0-6alkylCONHaιyl! -Co-6alkylNH2, -C0-6alkylNH(C1-6alkyl) or -C0-6alkylN(C1-6alkyl)2.
R1 is H, -CI, -Br, -I or -F, -OCF3, -OMe, NH2, NHMe, NHMe2, -NHCOMe, - NHSO2Me; and
R3 is H, -CI, -Br, -I, -F, -OCι-6alkyl, -NHCι-6acyl, -NO2, -NHSO2C1-4alkyl, -CN or -O(CH2)ι-4-COOH.
3. A compound of claim 1 , wherein:
A is a member selected from the group consisting of:
NH
R is, in each occurrence, independently, H, -d-βalkyl, -C -8cycloalkyl, -Co-ealkyl-OC^ 6alkyl, -C0-6alkyl-O(CH2)1-4-COOH, -C0-6alkyl-O(CH2)1-4-C(=O)OC1-C6alkyl, -C0-6alkylCOOH, -C0-6alkylCO2C1-6alkyl, -C0-6alkylOCι-6alkyl, -Cι-6alkylOH, -C0-6alkylCONH2, -C0-6allcylCONHC0-6alkyl; -C0-6alkylCON(C0-6alky)2, -Co-6alkylCON(CH2)2-6, -C0-6alkylCON(CH2CH2)2O, -C0-6alkylCON(CH2CH2)2SO2 -Co-6alkylCONHaryl! -C0-6alkylNH2, -C0-6alkylNH(C1-6alkyl) or -C0-6alkylN(Cι-6alkyl)2;
R1 is H, -CI, -Br, -I or -F, -OMe, NH2, NHMe, NHMe2, -NHCOMe, -NHSO2Me;
J1 is a member selected from the group consisting of:
X is O or S;
R3 is H, -CI, -Br, -I or -F;
R5 is H, -Cl, -Br, -I or -F;
J2 is a member selected from the group consisting of:
Z is -NR -, -O- or -S-
R is a H, C1-6 alkyl or C3-8 cycloalkyl;
R7 and R8 are each independently -CI, -Br, -I or -F; and
R and R are each independently -CI, -Br, -I or -F.
4. A compound of claim 1 of formula (I) having the following structure:
wherein: A is a member selected from the group consisting of:
10
-N , , ^OH
N'I OU2 N^ ^
1
IN^N^
Me H Me Me
A compound of claim 1 of formula (I) having the following structure:
wherein:
A is a member selected from the group consisting of:
NH NH NH NH
H 3 C. H,cN H3C.NA. sA
H02C Me02C H2NOC^ <£ T
V-0
CH.
M /— N -N
Et . c CH3 v C°2H <x *— C02Me
A compound of claim 1 of formula (I) having the following structure:
wherein:
Q is a member selected from the group consisting of:
F CI Br
-fΛ f\- _Ax_ -f\
an „d A \N ——Λ .,'
7. A compound of claim 1 of formula (I) having the following structure:
wherein:
A is a member selected from the group consisting of:
NH NH NH NH
H3C.N , H3C.NA. HsC.NA, H3C.NX
H , CH3 . J
H3C^ ' (>
CH3
NH NH NH NH
H3 C.NA. H3C.NA. H3C.NA. H3C.NA,
^-N VO ' O
8. A compound of claim 1 of formula (I) having the following structure:
wherein: R is independently selected from the group consisting of:
H, -CO2H, -CO2Me, -CONH2, -CONHMe, -CONHMe2, -CON(CH2)4, - CON(CH2)5, -CH2OH, -CH2OMe, -CH2CO2H, -CH2CO2Me, -CH2CONH2, -CH2CH2OH, -CH2CH2OMe, -CH2NH2, -CH2N(Me)2, and -CH3,
9. A compound of claim 1 of formula (I) having the following structure:
wherein:
R is independently selected from the group consisting of: H, -CO2H, -CO2Me, -CONH2, -CONHMe, -CONHMe2, -CON(CH2)4, -
CON(CH2)5, -CH2OH, -CH2OMe, -CH2CO2H, -CH2CO2Me, -CH2CONH2, -CH2CH2OH, -CH2CH2OMe, -CH2NH2, -CH2N(Me)2, and -CH3,
10. A compound of claim 1 of formula (I) having the following structure:
wherein:
A is a member selected from the group consisting of: NH NH NH NH
H3CNA. H3C.NA. H3C.NA. H3C.NA.
CH3
H3C )
CH,
NH NH NH NH
H3C.NA. H3C.NA, H3C.NA. H3C.NA.
OMe , NH2 , NHMe . ' „N
H3C r„ ' CH3
H3
H I
CH l Et . S CAH3 , N. *— C02 „H N> <— C02Me
NH NH NH s' ^ H2NΛA H2NΛN--
, Me π >
11. A compound of claim 1 of formula (I) having the following structure:
wherein:
J is a member selected from the group consisting of:
12. A compound of claim 1 of formula (II) having the following structure:
wherein: J1 is a member selected from the group consisting of:
0,N H2NQ2S Me02C Me02C, OMe x _ BRrr _AA _/ Brr _A n CιI -A y-cι
CI CI Me02S Me02S NC Ac AΛ. -OMe _ "V BBrr _/ o AV C!
OjN Me02S
H2NOC 02N
-Me
-CI AA -CI N=
H2N02S J>-OMe _ ~\ - ~\ OMe — < r,' N—N NHH2. A^ =N
13. A compound selected from the group consisting of:
and all pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives thereof. 5
14. A pharmaceutical composition for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of one of claims 1-13.
10
15. A method for preventing or treating a condition in a mammal characterized by undesired thrombosis comprising administering to said mammal a therapeutically effective amount of a compound of one of claims 1-13.
15 16. The method of claim 15, wherein the condition is selected from the group consisting of: acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post- coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic
20 stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep venous thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with
25 instrumentation such as cardiac or other intravascular catheterization, intra-aortic balloon pump, coronary stent or cardiac valve, and conditions requiring the fitting of prosthetic devices.
17. A method for inhibiting the coagulation of biological samples comprising the administration of a compound of one of claims 1-13.
AU2002211280A 2000-09-29 2001-10-01 Piperazin-2-one amides as inhibitors of factor Xa Abandoned AU2002211280A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23639300P 2000-09-29 2000-09-29
US60236393 2000-09-29
PCT/US2001/030313 WO2002026734A1 (en) 2000-09-29 2001-10-01 PIPERAZIN-2-ONE AMIDES AS INHIBITORS OF FACTOR Xa

Publications (1)

Publication Number Publication Date
AU2002211280A1 true AU2002211280A1 (en) 2002-04-08

Family

ID=22889303

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002211280A Abandoned AU2002211280A1 (en) 2000-09-29 2001-10-01 Piperazin-2-one amides as inhibitors of factor Xa

Country Status (7)

Country Link
US (1) US20040072860A1 (en)
EP (1) EP1322643A1 (en)
JP (1) JP2004509958A (en)
AU (1) AU2002211280A1 (en)
BR (1) BR0107282A (en)
CA (1) CA2422873A1 (en)
WO (1) WO2002026734A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI288745B (en) 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
WO2004083173A2 (en) * 2003-03-18 2004-09-30 Merck & Co., Inc. Ketopiperazine derivatives as bradykinin antagonists
WO2007008144A1 (en) * 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
WO2007008145A1 (en) * 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
US9045445B2 (en) 2010-06-04 2015-06-02 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56197C2 (en) * 1996-11-08 2003-05-15 Зенека Лімітед Heterocyclic derivatives
GB9715892D0 (en) * 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
EP1048652A4 (en) * 1997-12-26 2001-05-09 Mochida Pharm Co Ltd Aromatic compounds having cyclic amino or salts thereof
EP1051176B1 (en) * 1998-01-27 2006-11-22 Aventis Pharmaceuticals Inc. SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
WO1999040075A1 (en) * 1998-02-05 1999-08-12 Takeda Chemical Industries, Ltd. Sulfonamide derivatives, process for producing the same and utilization thereof
DE19835950A1 (en) * 1998-08-08 2000-02-10 Merck Patent Gmbh Piperazinone derivatives
JP2003529531A (en) * 1998-11-25 2003-10-07 アヴェンティス ファーマシューティカルズ インコーポレイテッド Substituted oxoazaheterocyclyl factor Xa inhibitors
EE200200045A (en) * 1999-07-28 2003-06-16 Aventis Pharmaceuticals Products Inc. Substituted oxoazaheterocyclyl compounds, pharmaceutical composition and intermediates

Also Published As

Publication number Publication date
US20040072860A1 (en) 2004-04-15
EP1322643A1 (en) 2003-07-02
BR0107282A (en) 2004-07-06
CA2422873A1 (en) 2002-04-04
JP2004509958A (en) 2004-04-02
WO2002026734A1 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
US6638980B1 (en) Inhibitors of factor Xa
US6545055B1 (en) Inhibitors of factor Xa
US20030114448A1 (en) Inhibitors of factor Xa
US6632815B2 (en) Inhibitors of factor Xa
US20040067938A1 (en) Quaternary amines and related inhibitors of factor xa
US20030069250A1 (en) Benzamide inhibitors of factor Xa
EP1185512A2 (en) INHIBITORS OF FACTOR Xa
US6686368B1 (en) Inhibitors of factor Xa
US6777413B2 (en) 2-[1H]-quinolone and 2-[1H]-quinoxalone inhibitors of factor Xa
US20040082786A1 (en) Piperazine based inhibitors of factor xa
EP1235807A1 (en) B-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factor xa
US6673817B1 (en) Inhibitors of factor Xa
WO2002026718A2 (en) Bicyclic pyrimidin-4-one based inhibitors of factor xa
US20040077690A1 (en) Quaternary amidino based inhibitors of factor xa
US20040072860A1 (en) Piperazin-2-one amides as inhibitors of factor xa
WO2002006280A2 (en) INHIBITORS OF FACTOR Xa
WO2001072725A1 (en) BICYCLIC SULFONYL AMINO INHIBITORS OF FACTOR Xa